Anti-peripheral lymph node addressin antibodies and uses thereof
Anti-PNAd antibodies provide selective immune modulation and targeted drug delivery, addressing the non-selectivity of current immunosuppressants by specifically targeting PNAd to manage immune-mediated diseases and tumors.
Patent Information
- Application Number
- JP2021547170
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-13
- Filing Date
- 2020-02-12
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2040-02-12
AI Technical Summary
Current immunosuppressive drugs lack selectivity and often cause major adverse drug reactions due to non-specific targeting of immune responses, which is a challenge in managing immune-mediated diseases and inflammatory conditions.
Development of anti-peripheral lymph node addressin (PNAd) antibodies and fragments that specifically target PNAd, allowing for selective modulation of lymphocyte trafficking and immune responses, conjugated with agents like contrast agents or drugs for targeted delivery to lymphoid tissues.
The PNAd-targeting antibodies effectively suppress lymphocyte-mediated immune responses, reduce inflammation, and inhibit tumor growth and metastasis by selectively delivering therapeutic agents to lymphoid tissues, thereby improving treatment outcomes with reduced side effects.
Smart Images

Figure 0007588080000005 
Figure 0007588080000006 
Figure 0007588080000007
Abstract
Description
[Technical field]
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 804,797, filed February 13, 2019, the entire contents of which are incorporated herein by reference.
[0002] The present invention relates to anti-peripheral lymph node addressin (PNAd) antibodies, antigen-binding fragments thereof and conjugates thereof and uses thereof. [Background technology]
[0003] Peripheral lymph node addressins (PNAds) are tissue-specific endothelial cell antigens constitutively expressed in high endothelial venules (HEVs) in both mice and humans. PNAds are a group of endothelial sialomucins, namely CD34, podocalixin, glycosylation-dependent cell adhesion molecule 1 (GlyCAM-1) and sialylated glycoprotein of 200 kDa (sgp200), all of which contain sulfated sialyl Lewis X (sLeX)-like motifs (von Andrian, UH & Mackay, CR, N Engl J Med 343: 1020-1034, 2000). PNAd is expressed in the venular endothelium of peripheral lymph nodes, tonsils, and almost all sites of inflammatory or lymphomatous lesions, but not in normal tissues of the ocular adnexa, thyroid, salivary glands, and lung (Liu Y, J Clin Exp Hematopathol 44 (1): 33-37, 2004). PNAd plays an important role in lymphocyte homing to inflammatory lesions and in the biological behavior of lymphoma cells in MALT lymphoma tissues of these organs.
[0004] Inflammation is a key pathogenic process in a great number of common diseases, from classical immune-mediated diseases such as rheumatoid arthritis to cancer. From graft rejection, where leukocytes infiltrate the transplanted organ, to multiple sclerosis, where lymphocytes infiltrate the brain, to atherosclerotic plaques, where leukocytes exacerbate lipid-induced micro- and macrovascular injury, immune or inflammatory responses are central to the development of these diseases. During the past decade, great progress has been made in the development of novel immunosuppressive drugs. These agents play a pivotal role in ensuring the success of organ transplantation and have greatly improved the outcomes of patients with life-threatening immune-mediated diseases. However, the use of immunosuppressants is hampered by a lack of selectivity and the frequently observed major adverse drug reactions. Summary of the Invention [Means for solving the problem]
[0005] The present disclosure provides anti-peripheral lymph node addressin (PNAd) antibodies or PNAd-binding fragments thereof and methods of using same.
[0006] In one aspect, the disclosure features an anti-peripheral lymph node addressin (PNAd) antibody, or a PNAd-binding fragment thereof, comprising: (a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and (b) a light chain variable region (VL) comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0007] In some embodiments, the VH comprises a VH framework region 1 (FR1) comprising the amino acid sequence set forth in SEQ ID NO:11, a VH FR2 comprising the amino acid sequence set forth in SEQ ID NO:12, a VH FR3 comprising the amino acid sequence set forth in SEQ ID NO:13, and a VH FR4 comprising the amino acid sequence set forth in SEQ ID NO:14.
[0008] In some embodiments, the VL comprises a VL FR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, a VL FR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, a VL FR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and a VL FR4 comprising the amino acid sequence set forth in SEQ ID NO: 18.
[0009] In some embodiments, the VH comprises the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the VL comprises the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the VH comprises the amino acid sequence set forth in SEQ ID NO: 2 and the VL comprises the amino acid sequence set forth in SEQ ID NO: 7.
[0010] In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a murine antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody.
[0011] In some embodiments, the antibody or PNAd-binding fragment thereof comprises human-derived heavy and light chain constant regions. In some embodiments, the antibody or PNAd-binding fragment thereof comprises a heavy chain constant region of the isotype immunoglobulin mu (IgM).
[0012] In some embodiments, the PNAd-binding fragment is selected from the group consisting of a single chain Fv fragment (scFv), a F(ab') fragment, a F(ab) fragment, and a F(ab')2 fragment.
[0013] In some embodiments, the antibody or PNAd-binding fragment thereof is conjugated to an agent. In some embodiments, the agent is an imaging agent, a cytotoxic agent, or a drug. In some embodiments, the agent is a drug-containing polymeric particle. In some embodiments, the drug-containing polymeric particle comprises an immunosuppressant or an immunomodulatory agent. In some embodiments, the conjugation to the agent is a covalent conjugation. In some embodiments, the conjugation to the agent is via a linker. In some embodiments, the linker is polyethylene glycol.
[0014] Also provided herein are polynucleotides comprising nucleic acid sequences encoding the above-described antibodies or PNAd-binding fragments thereof.
[0015] Further provided herein is a polynucleotide comprising a nucleic acid sequence encoding a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 1. In some examples, the polynucleotide is operably linked to a promoter.
[0016] Further provided herein is a polynucleotide comprising a nucleic acid sequence encoding a heavy chain, wherein the heavy chain comprises a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 1. In some examples, the polynucleotide is operably linked to a promoter.
[0017] Also provided herein is a polynucleotide comprising a nucleic acid sequence encoding a light chain variable region (VL), wherein the VL comprises the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 6. In some examples, the polynucleotide is operably linked to a promoter.
[0018] Also provided herein is a polynucleotide comprising a nucleic acid sequence encoding a light chain, the light chain comprising a light chain variable region (VL), the VL comprising the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the polynucleotide comprises the nucleic acid sequence set forth in SEQ ID NO: 6. In some examples, the polynucleotide is operably linked to a promoter.
[0019] Also provided herein is a vector comprising a promoter operably linked to a polynucleotide comprising a nucleic acid sequence encoding (i) a VH comprising the amino acid sequence set forth in SEQ ID NO:2 operably linked to a promoter, or (ii) a VL comprising the amino acid sequence set forth in SEQ ID NO:7.
[0020] Also provided herein is a vector comprising a promoter operably linked to the above-described polynucleotide comprising a nucleic acid sequence encoding a heavy chain comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:2.
[0021] Also provided herein is a vector comprising a promoter operably linked to the above-described polynucleotide comprising a nucleic acid sequence encoding a light chain comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:7.
[0022] Also provided herein is a vector comprising (i) a first promoter operably linked to said polynucleotide comprising a nucleic acid sequence encoding a heavy chain comprising a VH comprising the amino acid sequence set forth in SEQ ID NO:2, and (ii) a second promoter operably linked to said polynucleotide comprising a nucleic acid sequence encoding a light chain comprising a VL comprising the amino acid sequence set forth in SEQ ID NO:7.
[0023] Also provided herein is a host cell comprising one or more of the above polynucleotides operably linked to a promoter(s).
[0024] Also provided herein are host cells containing one or more of the above vectors.
[0025] Also provided herein is a method for producing an anti-peripheral lymph node addressin (PNAd) antibody or a PNAd-binding fragment thereof, comprising (a) culturing the host cell described above, and (b) isolating the antibody from the culture.
[0026] Also provided herein is a pharmaceutical composition comprising a therapeutically effective amount of the above-described antibody or PNAd-binding fragment thereof and a pharma- ceutically acceptable carrier.
[0027] Also provided herein is a method of suppressing a lymphocyte-mediated immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described above.
[0028] Also provided herein is a method of treating or slowing the progression of autoimmune diabetes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition.
[0029] Also provided herein is a method of treating lymphocyte-mediated inflammation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described above.
[0030] Also provided herein is a method of treating or reducing metastasis of a peripheral lymph node addressin (PNAd)-expressing malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition. In some embodiments, the PNAd-expressing malignancy is lymphoma. In some embodiments, the PNAd-expressing malignancy is cancer. In some examples, the cancer is breast cancer.
[0031] Also provided herein is a method of delivering a drug to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition, wherein the drug delivered to the subject is a drug of a drug-containing polymeric particle conjugated to an antibody or PNAd-binding fragment thereof of the pharmaceutical composition. In some embodiments, the drug is delivered to one or more lymphatic tissues or one or more sites of chronic inflammation in the subject.
[0032] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims. [Brief description of the drawings]
[0033] [Figure 1] 1A-B are diagrams showing that MHA112 monoclonal antibody (mAb) recognizes high endothelial venules (HEVs) in mice and humans. (Fig. 1A) Immunofluorescence staining showed low magnification images of HEV staining by MHA112 mAb. Scale bar, 500 μm. (Fig. 1B) Immunofluorescence staining showed high magnification images of HEV staining by MHA112 mAb in mouse lymph nodes (LNs) and human tonsils. Scale bar, 100 μm. [Diagram 2] Figure 2 shows MHA112 mAb isotyping. MHA112 mAb isotype was determined by isotyping enzyme-linked immunosorbent assay (ELISA). Absorbance was recorded at 450 nm. [Diagram 3] Figure 3A-B shows the transport of MHA112 mAb-conjugated nanoparticles (NPs) into LNs. (Figure 3A) Fluorescence images showed the distribution of MHA112 mAb-conjugated NPs (MHA112-IR800-NPs) in various LNs. NPs only (IR800-NPs) were used as a negative control, and MECA79-NPs (MECA79_IR800-NPs) were used as a positive control. (Figure 3B) Immunofluorescence analysis of MECA79-NPs and MHA112-NPs distribution in axillary LNs. HEVs were stained in green, and IR800 dye in NPs was stained in red. Scale bar, 50 μm. [Figure 4]Figure 4. Flow cytometry profiling of labeled T cell homing to LNs in control (PBS, MECA79) and MHA112 mAb treated groups showing that MHA112 mAb, but not MECA79 mAb, blocked T cell homing to LNs. Data from 3 mice / group (n=3) show the change in percentage of labeled T cells and are summarized in a bar graph. *p<0.05, **p<0.01, ***p<0.001, t-test. ns: not significant. [Diagram 5] 5 is a diagram showing the MHA112 sequence. The sequences of the MHA112 heavy and light chain variable regions (VH and VL, respectively) are shown, with the framework regions (FR1-FR4) and IMGT complementarity determining regions (CDR1-CDR3) depicted. VH=SEQ ID NO:2, VH FR1-FR4=SEQ ID NOs:11-14, respectively, VH CDR1-3=SEQ ID NOs:3-5, respectively, VL=SEQ ID NO:7, VL FR1-FR4=SEQ ID NOs:15-18, respectively, VL CDR1-3=SEQ ID NOs:3-5, respectively. [Figure 6] Figure 6 shows the determination of binding affinity of MECA79 and MHA112 mAbs by ELISA. Various concentrations of MECA79 and MHA112 were tested on CHO-PNAd cells. Kd was calculated. MHA112 was found to have better binding affinity than MECA79. [Figure 7] FIG. 7 shows breast tumor growth curves demonstrating significantly slower growth of 4T1 mouse breast tumors in BALB / c-WT mice treated with free taxol and MHA112-taxol (equivalent to 160 ng free taxol, iv q2d for 33 days post-implantation) (n=12) than the control group treated with PBS (n=12). Data are presented as mean + / - SD. **P<0.01, ***P<0.001. Triangles on the x-axis indicate injection points. The MHA112-taxol group had significantly smaller tumor size compared to the free taxol and untreated groups. [Figure 8]FIG. 8. Fluorescence micrographs of breast tumor draining lymph nodes (DLN) show that the MHA112-Taxol group had less extensive HEV and LYVE1+ lymphatic vessels (green) than the control or free Taxol groups. Pan-cytokeratin (red) indicates 4T1 metastasis in TDLN. Scale bar: 100 μm. The MHA112-Taxol group showed significantly less tumor metastasis as well as lymphatic spread compared to the free Taxol and untreated groups. [Figure 9] Figure 9 shows fluorescent micrographs of breast tumor DLN showing less severe fibrosis (as indicated by collagen I, collagen IV and laminin) in the MHA112-taxol group than in the control or free taxol groups. Scale bar: 100 μm. The MHA112-taxol group showed significantly less lymph node fibrosis compared to the free taxol and untreated groups. [Figure 10] Figure 10 shows survival curves showing significantly longer survival of 4T1 breast tumor liver portal vein metastasis model (n=5) receiving MHA112-taxol compared to control and free taxol groups. ***P<0.001. Triangles represent the day of injection. [Figure 11] Figure 11 shows the survival curves of panc02 pancreatic tumors in the pancreas, with MHA112-taxol (n=5) showing significantly longer survival than control and free taxol (n=5). Triangles indicate injection points. ***P<0.001 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0034] I. Definition It should be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "an antibody" is understood to refer to one or more antibodies. As such, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.
[0035] As used herein, the term "polypeptide" is intended to encompass the singular "polypeptide" as well as the plural "polypeptides" and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any chain or chains of two or more amino acids and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "proteins," "amino acid chains," or any other term used to refer to a chain or chains of two or more amino acids are included within the definition of "polypeptide," and the term "polypeptide" may be used in place of or synonymously with any of these terms.
[0036] The term "polypeptide" also refers to the products of post-expression modifications of the polypeptide, including, but not limited to, glycosylation, acetylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, or modification with non-naturally occurring amino acids. Polypeptides may be derived from natural biological sources or produced by recombinant technology, but are not necessarily translated from a designated nucleic acid sequence. They may be made in any manner, including by chemical synthesis.
[0037] The polypeptides described herein may be about 3 or more, 5 or more, 10 or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more, 500 or more, 1,000 or more, or 2,000 or more amino acids in size. Polypeptides may have a defined three-dimensional structure, but they do not necessarily have such a structure. Polypeptides that have a defined three-dimensional structure are called folded, and polypeptides that do not have a defined three-dimensional structure, but rather can adopt a number of different conformations, are called unfolded. As used herein, the term glycoprotein refers to a protein coupled to at least one carbohydrate moiety that is attached to the protein via an oxygen- or nitrogen-containing side chain of an amino acid residue, e.g., a serine or asparagine residue.
[0038] An "isolated" polypeptide or a fragment, variant or derivative thereof is intended to be a polypeptide that is not in its natural environment. No particular level of purification is required. For example, an isolated polypeptide may be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells, as well as natural or recombinant polypeptides that have been separated, fractionated, or partially or substantially purified by any suitable technique, are considered to be isolated for the purposes described herein.
[0039] Also included as polypeptides are fragments, derivatives, analogs or variants of the aforementioned polypeptides and any combination thereof. The terms "fragment", "variant", "derivative" and "analog", when referring to an antibody or antibody polypeptide described herein, include any polypeptide that retains at least a portion of the antigen-binding properties of the corresponding native binding molecule, antibody or polypeptide. Fragments of the polypeptides described herein include proteolytic fragments as well as deletion fragments, in addition to the specific antibody fragments discussed elsewhere herein. Variants of the antibodies and antibody polypeptides described herein include fragments as described above and also polypeptides having altered amino acid sequences by amino acid substitutions (e.g., conservative or non-conservative amino acid substitutions), deletions or insertions. Variants may be naturally occurring or non-naturally occurring. Non-naturally occurring variants may be generated using mutagenesis techniques known in the art. Variant polypeptides may include conservative or non-conservative amino acid substitutions (e.g., conservative or non-conservative amino acid substitutions), deletions or additions. Derivatives of the PNAd-specific binding molecules described herein, such as antibodies and antibody polypeptides, are polypeptides that have been altered to exhibit additional features not found in the native polypeptide. Examples include fusion proteins. Variant polypeptides may also be referred to herein as "polypeptide analogs." As used herein, a "derivative" of a binding molecule or fragment thereof, an antibody or antibody polypeptide refers to a subject polypeptide that has one or more residues that have been chemically derivatized by reaction of a functional side chain. Also included as "derivatives" are those that contain one or more naturally occurring amino acid derivatives of the 20 standard amino acids. For example, 4-hydroxyproline may be replaced with proline, 5-hydroxylysine may be replaced with lysine, 3-methylhistidine may be replaced with histidine, homoserine may be replaced with serine, and ornithine may be replaced with lysine.
[0040] The term "polynucleotide" is intended to encompass the singular form of nucleic acid as well as the plural form of nucleic acid, and refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA) or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or non-conventional bonds (e.g., amide bonds such as those found in peptide nucleic acids (PNAs)). The term "nucleic acid" refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide. By "isolated" nucleic acid or polynucleotide is intended a nucleic acid molecule, DNA or RNA, that has been removed from its natural environment. For example, a recombinant polynucleotide encoding an antibody contained in a vector is considered isolated for the purposes described herein. Further examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the polynucleotides described herein. The isolated polynucleotides or nucleic acids described herein further include such molecules produced synthetically. In addition, a polynucleotide or nucleic acid may be or may include regulatory elements such as a promoter, ribosome binding site, or transcription terminator.
[0041] As used herein, a "coding region" is a portion of a nucleic acid consisting of codons that are translated into amino acids. A "stop codon" (TAG, TGA, or TAA) may be considered to be part of a coding region, even though it is not translated into an amino acid, while any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, etc., are not part of a coding region. Two or more coding regions described herein may be present in a single polynucleotide construct, e.g., on a single vector, or in separate polynucleotide constructs, e.g., on separate (different) vectors. Furthermore, any vector may contain a single coding region or may include two or more coding regions, e.g., a single vector may separately encode an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region. Additionally, the vectors, polynucleotides, or nucleic acids described herein may encode heterologous coding regions, fused or unfused to the nucleic acid encoding a binding molecule, an antibody, or a fragment, variant, or derivative thereof. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains.
[0042] In some embodiments, the polynucleotide or nucleic acid is DNA. In the case of DNA, a polynucleotide comprising a nucleic acid encoding a polypeptide may usually include a promoter and / or other transcription or translation control elements operably associated with one or more coding regions. Operable association is when a coding region of a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way that expression of the gene product is placed under the influence or control of the regulatory sequence(s). Two DNA fragments (e.g., a polypeptide coding region and its associated promoter) are "operably associated" or "operably linked" when induction of promoter function results in transcription of an mRNA encoding a desired gene product, and when the nature of the link between the two DNA fragments does not interfere with the ability of the expression regulatory sequence to direct expression of the gene product or the ability of the DNA template to be transcribed. Thus, a promoter region would be operably associated with a nucleic acid encoding a polypeptide if the promoter was capable of effecting transcription of that nucleic acid. The promoter may be a cell-specific promoter that directs substantial transcription of the DNA only in a given cell. Other transcription control elements, in addition to a promoter, such as enhancers, operators, repressors, and transcription termination signals, can be operably associated with the polynucleotide to direct cell-specific transcription. Suitable promoters and other transcription control regions are disclosed herein.
[0043] A variety of transcription control regions are known to those skilled in the art. These include, but are not limited to, transcription control regions that function in vertebrate cells, such as, but not limited to, promoters and enhancer segments from cytomegalovirus (immediate early promoter, with intron A), simian virus 40 (early promoter) and retroviruses (such as Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone and rabbit β-globin, as well as other sequences that can control gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers and lymphokine-inducible promoters (e.g., promoters that can be induced by interferon or interleukin).
[0044] Similarly, a variety of translation control elements are known to those of skill in the art, including, but not limited to, ribosome binding sites, translation initiation and termination codons, and elements derived from picornaviruses (particularly internal ribosome entry sites or IRES, also called CITE sequences).
[0045] In some embodiments, the polynucleotides described herein are RNA, for example in the form of messenger RNA (mRNA).
[0046] The polynucleotide and nucleic acid coding regions described herein may be associated with additional coding regions that encode secretory or signal peptides that direct the secretion of the polypeptides encoded by the polynucleotides described herein. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein once the export of the growing protein chain across the rough endoplasmic reticulum is initiated. Those skilled in the art are aware that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide that is cleaved from the complete or "full-length" polypeptide to result in the secreted or "mature" form of the polypeptide. In some embodiments, a native signal peptide is used, such as an immunoglobulin heavy or light chain signal peptide or a functional derivative thereof that is operably associated therewith and retains the ability to direct the secretion of the polypeptide. Alternatively, a heterologous mammalian signal peptide or a functional derivative thereof may be used. For example, the wild-type leader sequence may be replaced with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.
[0047] Unless otherwise indicated, the terms "disorder" and "disease" are used interchangeably by the inventors.
[0048] "Binding molecule," as used herein, primarily relates to antibodies and fragments thereof, but may also refer to other non-antibody molecules that bind to PNAd, including, but not limited to, hormones, receptors, ligands, major histocompatibility complex (MHC) molecules, chaperones, such as heat shock proteins (HSPs), and intercellular adhesion molecules, such as cadherins, integrins, C-type lectins, and members of the immunoglobulin (Ig) superfamily. Thus, most of the following embodiments are discussed in terms of antibodies and antibody-like molecules, which represent specific embodiments of binding molecules for the development of therapeutic and diagnostic agents, merely for clarity and without limiting the scope of the present disclosure.
[0049] The terms "antibody" and "immunoglobulin" are used interchangeably herein. An antibody or immunoglobulin is a PNAd-binding molecule that contains at least a heavy chain variable domain, and usually contains at least a heavy and a light chain variable domain. Basic immunoglobulin structure in vertebrate systems is relatively well understood, see, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988).
[0050] As discussed in more detail below, the term "immunoglobulin" includes various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (γ, μ, α, δ, ε), with several subclasses in between (e.g., γ1-γ4). It is the nature of this chain that determines the "class" of an antibody, IgG, IgM, IgA IgG, or IgE, respectively. Immunoglobulin subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, etc., have been well characterized and are known to confer functional specialization. Modified versions of each of these classes and isotypes are readily discernible to one of skill in the art in light of the present disclosure, and thus are within the scope of the present disclosure. All immunoglobulin classes are expressly within the scope of the present disclosure, and the following discussion will generally be directed to the IgG class of immunoglobulin molecules. For IgG, a standard immunoglobulin molecule contains two identical light polypeptide chains of molecular weight approximately 23,000 daltons and two identical heavy polypeptide chains of molecular weight 53,000-70,000. The four chains are usually joined by disulfide bonds in a "Y" configuration, with the light chains surrounding the heavy chains, which begin at the mouth of the "Y" and continue through the variable region.
[0051] Light chains are classified as either kappa or lambda (κ, λ). Each heavy chain class can be associated with either a kappa or lambda light chain. Generally, light and heavy chains are covalently linked to each other, and the "tail" portions of the two heavy chains are linked to each other by covalent disulfide bonds or non-covalent linkages when the immunoglobulin is produced by either a hybridoma, a B cell, or a genetically engineered host cell. In the heavy chain, the amino acid sequence extends from the N-terminus at the branched end of the Y configuration to the C-terminus at the bottom of each chain.
[0052] Both light and heavy chains are divided into regions of structural and functional homology. The terms "constant" and "variable" are used functionally. In this regard, it will be appreciated that the variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light (CL) and heavy chains (CH1, CH2 or CH3) confer important biological properties, such as secretion, transplacental mobility, Fc receptor binding, complement binding, etc. By convention, the numbering of the constant region domains increases as they become more distal from the antigen-binding site or amino terminus of the antibody. The N-terminal portion is the variable region, the C-terminal portion is the constant region, and the CH3 and CL domains actually comprise the carboxy termini of the heavy and light chains, respectively.
[0053] As indicated above, the variable region allows the antibody to selectively recognize and specifically bind to an epitope on an antigen. That is, the VL domain and the VH domain or a subset of the complementarity determining regions (CDRs) of an antibody combine to form the variable region, which defines a three-dimensional antigen binding site. This quaternary antibody structure forms the antigen binding site present at the end of each arm of the Y. More specifically, the antigen binding site is defined by three CDRs each of the VH and VL chains. Any antibody or immunoglobulin fragment that contains sufficient structure to specifically bind to a PNAd is interchangeably referred to herein as a "binding fragment" or an "immunospecific fragment."
[0054] In naturally occurring antibodies, antibodies contain six hypervariable regions, sometimes called "complementarity determining regions" or "CDRs", present in each antigen-binding domain, which are short, non-contiguous sequences of amino acids specifically arranged to form the antigen-binding domain as the antibody assumes its three-dimensional configuration in an aqueous environment. The "CDRs" are flanked by four relatively conserved "framework" regions or "FRs" that show little intermolecular variability. The framework regions largely adopt a β-sheet conformation, and the CDRs form loops that connect and in some cases form part of the β-sheet structure. Thus, the framework regions act to form a scaffold for positioning the CDRs in the correct orientation by interchain non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface that is complementary to the epitope on the immunoreactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its cognate epitope. The amino acids which comprise the CDRs and framework regions, respectively, can be readily identified by one of skill in the art for any given heavy or light chain variable region because they have been precisely defined; see "Sequences of Proteins of Immunological Interest," Kabat, E., et al., US Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196 (1987), 901-917, which are incorporated by reference herein in their entireties.
[0055] In the event that there is more than one definition of a term used and / or accepted within the art, the definition of the term as used herein shall include all such meanings unless expressly stated to the contrary. A particular example is the use of the term "complementarity determining region" ("CDR") to describe non-contiguous antigen combining sites combining sites found within the variable regions of both heavy and light chain polypeptides. This particular region is described by Kabat et al., US Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and Chothia and Lesk, J. Mol. Biol., 196 (1987), 901-917, which are incorporated herein by reference, in which the definitions include overlapping amino acid residues or subsets of amino acid residues when compared with each other. Nevertheless, application of either definition to refer to the CDR of an antibody or variant thereof shall be within the scope of the term as defined and used herein. The appropriate amino acid residues encompassing the CDRs as defined by each of the above cited references are set forth below in Table 1 for comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. One of skill in the art can routinely determine which residues encompass a particular hypervariable region or CDR of a human IgG subtype of antibody, given the variable region amino acid sequence of the antibody.
[0056] [Table 1]
[0057] Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of "Kabat numbering" to any variable domain sequence without relying on any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system presented by Kabat et al., US Dept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise stated, references to the numbering of specific amino acid residue positions in an antibody or antigen-binding fragment, variant or derivative thereof described herein are according to the Kabat numbering system, which is theoretical and may not apply equally to every antibody described herein. For example, depending on the position of the first CDR, subsequent CDRs may be moved in either direction.
[0058] Antibodies or antigen-binding, immunospecific fragments, variants or derivatives thereof described herein include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, primatized, murine or chimeric antibodies, single chain antibodies, epitope-binding fragments such as Fab, Fab' and F(ab')2, Fd, Fv, single chain Fv (scFv), single chain antibodies, disulfide-linked Fv (sdFv), fragments containing either the VL or VH domain, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies against the antibodies disclosed herein). ScFv molecules are known in the art and are described, for example, in U.S. Pat. No. 5,892,019. The immunoglobulin or antibody molecules described herein can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.
[0059] In some embodiments, the antibody is not an IgM or a derivative thereof having a pentavalent structure. In particular, for certain applications, particularly therapeutic uses, IgM is less useful than IgG and other bivalent antibodies or corresponding binding molecules, since IgM often exhibits non-specific cross-reactivity and very low affinity due to its pentavalent structure and lack of affinity maturation.
[0060] In some embodiments, the antibody is an IgM or a derivative thereof having a pentavalent structure.
[0061] In some embodiments, the antibody is not a polyclonal antibody, ie, it is substantially composed of one specific antibody species, rather than a mixture obtained from a plasma immunoglobulin sample.
[0062] Antibody fragments, including single chain antibodies, may comprise variable region(s) alone or in combination with the whole or part of the following: hinge region, CH1, CH2 and CH3 domains. Also provided herein are PNAd-binding fragments that comprise any combination of variable region(s) with hinge region, CH1, CH2 and CH3 domains. The antibodies or immunospecific fragments thereof described herein may be of any animal origin, including birds and mammals. In some embodiments, the antibodies are human, murine, donkey, rabbit, goat, guinea pig, camel, llama, horse or chicken antibodies. In another embodiment, the variable region may be chondricthoid in origin (e.g., from shark).
[0063] In some embodiments, the antibody is a human monoclonal antibody isolated from a human. Optionally, the framework region of the human antibody is aligned and adopted according to the relevant human germline variable region sequence in a database; see, for example, Vbase (vbase.mrc-cpe.cam.ac.uk) hosted by the MRC Protein Engineering Centre (Cambridge, UK). For example, the amino acids that are considered to be likely to deviate from the true germline sequence may be due to PCR primer sequences incorporated during the cloning process. Compared to artificially produced human-like antibodies, such as single-chain antibody fragments (scFv) obtained from phage-displayed antibody libraries or xenogeneic mice, the human monoclonal antibodies described herein are characterized by (i) being obtained using a human immune response rather than an animal surrogate, i.e., the antibody is produced in response to natural PNAd in its relevant conformation in the human body; (ii) having protected the individual or at least significantly for the presence of PNAd; and (iii) the risk of cross-reactivity against self-antigens is minimized, since the antibody is of human origin. Thus, as used herein, the terms "human monoclonal antibody," "human monoclonal autoantibody," "human antibody," and the like are used to refer to PNAd-binding molecules that are of human origin, i.e., isolated from a human cell, e.g., a B cell or a hybridoma thereof, or from a cDNA that has been cloned directly from the mRNA of a human cell, e.g., a human memory B cell. A human antibody remains "human" even if amino acid substitutions have been made in the antibody, e.g., to improve binding characteristics.
[0064] Antibodies derived from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulins and which do not express endogenous immunoglobulins, as described below and for example in U.S. Pat. No. 5,939,598 by Kucherlapati et al., are referred to as human-like antibodies to distinguish them from the truly human antibodies described herein.
[0065] For example, the pairing of heavy and light chains of human-like antibodies, such as synthetic and semi-synthetic antibodies, isolated from phage display usually does not necessarily reflect the original pairing as it occurred in the original human B cell. Therefore, Fab and scFv fragments obtained from recombinant expression libraries, as often used in the prior art, can be considered artificial and with all possible associated effects on immunogenicity and stability.
[0066] As used herein, the term "heavy chain portion" includes an amino acid sequence derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain portion includes at least one of a CH1 domain, a hinge (e.g., upper, middle and / or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof. For example, a binding polypeptide for use in the methods described herein may include a polypeptide chain comprising a CH1 domain, a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain and a CH2 domain, a polypeptide chain comprising a CH1 domain and a CH3 domain, a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain and a CH3 domain, or a polypeptide chain comprising a CH1 domain, at least a portion of a hinge domain, a CH2 domain and a CH3 domain. In another embodiment, a polypeptide described herein includes a polypeptide chain comprising a CH3 domain. Furthermore, a binding polypeptide for use in the methods described herein may lack at least a portion of a CH2 domain (e.g., all or a portion of a CH2 domain). As noted above, it will be understood by those skilled in the art that these domains (eg, the heavy chain portions) may be modified such that they vary in amino acid sequence from naturally occurring immunoglobulin molecules.
[0067] In certain antibodies or their antigen-binding fragments, variants or derivatives disclosed herein, the heavy chain portion of one polypeptide chain of multimer is the same as that on the second polypeptide chain of multimer.Alternatively, the monomers that contain the heavy chain portion described herein are not the same.For example, each monomer can contain different target binding sites, for example, to form a bispecific antibody or diabody.
[0068] In some embodiments, the antibodies or antigen-binding fragments, variants, or derivatives disclosed herein are composed of a single polypeptide chain, e.g., an scFv, and should be expressed intracellularly (intrabody) for potential in vivo therapeutic and diagnostic applications.
[0069] The heavy chain portion of the binding polypeptide for use in the diagnostic and treatment methods disclosed herein can be derived from different immunoglobulin molecules.For example, the heavy chain portion of the polypeptide can comprise a CH1 domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule.In another example, the heavy chain portion can comprise a hinge region that is partly derived from an IgG1 molecule and partly derived from an IgG3 molecule.In another example, the heavy chain portion can comprise a chimeric hinge that is partly derived from an IgG1 molecule and partly derived from an IgG4 molecule.
[0070] As used herein, the term "light chain portion" includes amino acid sequences derived from an immunoglobulin light chain. In some embodiments, a light chain portion includes at least one of a VL or CL domain.
[0071] The minimum size of a peptide or polypeptide epitope of an antibody is believed to be about 4-5 amino acids. A peptide or polypeptide epitope may contain at least 7, at least 9, or between at least about 15 and about 30 amino acids. Since the CDR can recognize an antigenic peptide or polypeptide in its tertiary form, the amino acids comprising the epitope need not be contiguous, and in some cases may not even be on the same peptide chain. In some embodiments, a peptide or polypeptide epitope recognized by an antibody described herein contains a sequence of at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, or between about 5 to about 30, about 10 to about 30, or about 15 to about 30 contiguous or non-contiguous amino acids of the PNAd.
[0072] "Specifically bind" or "specifically recognize", used interchangeably herein, generally means that a binding molecule, e.g., an antibody, binds to an epitope via an antigen-binding domain, and that binding requires some complementarity between the antigen-binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an epitope if it binds to that epitope more readily through its antigen-binding domain than it would to a random, unrelated epitope. Those skilled in the art will understand that an antibody may specifically bind or specifically recognize an isolated polypeptide that includes or consists of amino acid residues that correspond to a linear portion of a non-contiguous epitope. The term "specificity" is used herein to qualify the relative affinity with which a particular antibody binds to a particular epitope. For example, antibody "A" may be deemed to have a higher specificity for a given epitope than antibody "B", or antibody "A" may be said to bind epitope "C" with a higher specificity than it has for related epitope "D".
[0073] When present, the term "immunological binding characteristics" of an antibody with an antigen or other binding characteristics refers to the specificity, affinity, cross-reactivity and other binding characteristics of the antibody in all of its grammatical forms.
[0074] "Preferentially binds" means that a binding molecule, e.g., an antibody, specifically binds to an epitope more readily than it would bind to a related, similar, homologous, or analogous epitope. Thus, an antibody that "preferentially binds" to a given epitope will be more likely to bind to that epitope than to a related epitope, even if such an antibody may cross-react with the related epitope.
[0075] As a non-limiting example, a binding molecule, e.g., an antibody, can be used to bind to a first epitope and to bind to a second epitope. D A dissociation constant (K D In another non-limiting example, an antibody may be considered to preferentially bind to the first epitope when it binds to the first epitope at a K D In another non-limiting example, an antibody may be considered to preferentially bind a first antigen if it binds to the first epitope with an affinity at least one order of magnitude less than the K of the antibody for the second epitope. D A first epitope can be considered to be preferentially bound if it binds with an affinity that is at least two orders of magnitude less than the first epitope.
[0076] In another non-limiting example, a binding molecule, e.g., an antibody, may be considered to bind preferentially to a first epitope if it binds to the first epitope with an off-rate (k(off)) that is less than the antibody's k(off) for the second epitope. In another non-limiting example, an antibody may be considered to bind preferentially to a first epitope if it binds to the first epitope with an affinity that is at least one order of magnitude less than the antibody's k(off) for the second epitope. In another non-limiting example, an antibody may be considered to bind preferentially to a first epitope if it binds to the first epitope with an affinity that is at least two orders of magnitude less than the antibody's k(off) for the second epitope.
[0077] A binding molecule, for example, an antibody, is said to competitively inhibit the binding of a reference antibody to a given epitope if it preferentially binds to that epitope to such an extent that it blocks the binding of the reference antibody to that epitope to some extent.Competitive inhibition can be determined by any method known in the art, for example, competitive ELISA assay.An antibody is said to competitively inhibit the binding of a reference antibody to a given epitope by at least 90%, at least 80%, at least 70%, at least 60% or at least 50%.Those skilled in the art understand that the binding of an antibody to its epitope can also be competitively inhibited by a binding molecule that is not an antibody.
[0078] As used herein, the term "affinity" refers to the measure of the strength of binding of an individual epitope to a binding molecule, e.g., the CDR of an immunoglobulin molecule; see, e.g., Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. (1988) at pages 27-28. As used herein, the term "avidity" refers to the overall stability of the complex between a population of immunoglobulins and an antigen, i.e., the functional combining power of an immunoglobulin mixture with an antigen; see, e.g., Harlow at pages 29-34. Avidity is related to both the affinity of individual immunoglobulin molecules in a population with a specific epitope and also the binding valency of the immunoglobulin and the antigen. For example, the interaction between a bivalent monoclonal antibody and an antibody with a highly repetitive epitope structure, e.g., a polymer, will be of high avidity. The affinity or avidity of an antibody to an antigen can be empirically determined by any suitable method; see, for example, Berzofsky et al., "Antibody-Antigen Interactions" In Fundamental Immunology, Paul, WE, Ed., Raven Press New York, NY (1984), Kuby, Janis Immunology, WH Freeman and Company New York, NY (1992) and the methods described herein. Common techniques for measuring the affinity of an antibody to an antigen include ELISA, RIA and surface plasmon resonance. The measured affinity of a particular antibody-antigen interaction may vary when measured under different conditions, such as salt concentration, pH. Thus, affinity and other antigen binding parameters, such as K D Preferably, IC50 determinations are performed using standardized solutions of antibody and antigen and standardized buffers.
[0079] The binding molecule described herein, for example, antibody or its antigen-binding fragment, variant or derivative, can also be described and specified in terms of its cross-reactivity.As used herein, the term "cross-reactivity" refers to the ability of an antibody specific for one antigen to react with a second antigen; it is the measure of the association between two different antigenic substances.Thus, an antibody is cross-reactive when it binds to an epitope other than the one that induces its formation.Cross-reactive epitopes generally contain many of the same complementary structural features as induced epitopes, and in some cases, they may actually fit better than the original one.
[0080] For example, a certain antibody has a degree of cross-reactivity in that it binds to related but non-identical epitopes, such as epitopes that have at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55% and at least 50% identity (as calculated using methods known in the art and described herein) to the reference epitope. An antibody may be said to have little or no cross-reactivity if it does not bind to epitopes that have less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%, less than 60%, less than 55% and less than 50% identity (as calculated using methods known in the art and described herein) to the reference epitope. An antibody may be considered to be "highly specific" for a particular epitope if it does not bind to any other analogs, orthologs, or homologs of that epitope.
[0081] The binding molecules described herein, such as antibodies or antigen-binding fragments, variants, or derivatives thereof, may also be described and specified in terms of their binding affinity to PNAd.
[0082] As previously indicated, the subunit structures and three-dimensional configurations of the constant regions of various immunoglobulin classes are well known. As used herein, the term "VH domain" includes the amino-terminal variable domain of an immunoglobulin heavy chain, and the term "CH1 domain" includes the first (most amino-terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino-terminal to the hinge region of an immunoglobulin heavy chain molecule.
[0083] As used herein, the term "CH2 domain" includes, for example, the portion of a heavy chain molecule that extends from about residue 244 to residue 360 of an antibody using conventional numbering schemes (residues 244-360, Kabat numbering system; and residues 231-340, EU numbering system; see Kabat EA et al., supra). The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are inserted between the two CH2 domains of an intact native IgG molecule. It is also well documented that the CH3 domain extends from the CH2 domain to the C-terminus of the IgG molecule and comprises approximately 108 residues.
[0084] As used herein, the term "hinge region" includes the portion of a heavy chain molecule that connects the CH1 domain to the CH2 domain. This hinge region contains approximately 25 residues and is flexible, thus allowing the two N-terminal antigen-binding regions to move independently. The hinge region can be divided into three separate domains: upper, middle, and lower hinge domains; Roux et al., J. Immunol. 161 (1998), 4083.
[0085] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms. The amino acid cysteine contains a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CL regions are linked by disulfide bonds, and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (positions 226 or 229, EU numbering system).
[0086] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably. These terms refer to the joining of two or more elements or components together, whether by chemical conjugation or by recombinant means. An "in-frame fusion" refers to the joining of two or more polynucleotide open reading frames (ORFs) to form a continuous, longer ORF in a manner that maintains the correct translational reading frame of the original ORFs. Thus, a recombinant fusion protein is a single protein that contains two or more segments that correspond to the polypeptides encoded by the original ORFs (these segments are not normally joined in nature as such). Although the reading frame is thus made continuous throughout the fused segments, the segments may be physically or spatially separated, for example, by in-frame linker sequences. For example, polynucleotides encoding the CDRs of immunoglobulin variable regions may be fused in frame, but separated by polynucleotides encoding at least one immunoglobulin framework region or additional CDR regions, so long as the "fused" CDRs are co-translated as part of a continuous polypeptide.
[0087] The term "expression" as used herein refers to the process by which a gene produces a biochemical substance, e.g., an RNA or a polypeptide. The process includes any manifestation of the functional presence of a gene in a cell, including, but not limited to, gene knockdown and both transient and stable expression. It includes, but is not limited to, transcription of a gene into messenger RNA (mRNA), transfer RNA (tRNA), small hairpin RNA (shRNA), small interfering RNA (siRNA) or any other RNA product and translation of mRNA into a polypeptide(s). When the final desired product is a biochemical, expression includes the creation of that biochemical and any precursors. Expression of a gene produces a "gene product." As used herein, a gene product can be either a nucleic acid, e.g., a messenger RNA produced by transcription of a gene, or a polypeptide translated from a transcript. Gene products as described herein further include nucleic acids having post-transcriptional modifications, e.g., polyadenylation, or polypeptides having post-translational modifications, e.g., methylation, glycosylation, lipid addition, association with other protein subunits, proteolytic cleavage, and the like.
[0088] As used herein, the term "sample" refers to any biological material obtained from a subject or patient. In one embodiment, the sample may include blood, plasma, or urine. In other embodiments, the sample may include whole blood, plasma, B cells enriched from a blood sample, and cultured cells (e.g., B cells obtained from a subject). The sample may also include biopsies or tissue samples, including neural tissue. In yet other embodiments, the sample may include whole cells and / or cell lysates. Blood samples may be collected by methods known in the art. In one embodiment, the pellet may be resuspended by vortexing in 200 μl of buffer (20 mM Tris, pH 7.5, 0.5% Nonidet, 1 mM EDTA, 1 mM PMSF, 0.1 M NaCl, IX Sigma protease inhibitors, and IX Sigma phosphatase inhibitors 1 and 2) at 4° C. The suspension may be kept on ice for 20 minutes with intermittent vortexing. After centrifugation at 15,000 xg for 5 minutes at 4°C, aliquots of the supernatant may be stored at approximately -70°C.
[0089] As used herein, the term "treat" or "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, the purpose being to prevent or slow down (reduce) the undesired physiological changes or disorders described herein. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, whether detectable or undetectable, reduction in the extent of disease, a stabilized (i.e., no worsening) state of disease, delay or slowing of disease progression, remission or mitigation and remission (whether partial or complete) of the disease state. "Treatment" may also mean prolonging survival compared to expected survival in the absence of treatment. Those in need of treatment include those already with a condition or disorder as well as those prone to have a condition or disorder or those in whom the manifestation of a condition or disorder should be prevented.
[0090] By "subject" or "individual" or "animal" or "patient" or "mammal" is meant any subject, particularly a mammalian subject, e.g., a human patient, for whom diagnosis, prognosis, prevention, or therapy is desired.
[0091] A composition or method described herein that comprises components or steps may also consist essentially of or consist of those components or steps.
[0092] II. Antibodies Anti-peripheral lymph node addressin (PNAd) antibodies and antigen-binding fragments thereof are provided. Also provided herein are derivatives or variants of anti-PNAd antibodies or antigen-binding fragments thereof. Also provided herein are conjugates comprising such antibodies or PNAd-binding fragments or derivatives or variants thereof. In some embodiments, the antibodies or PNAd-binding fragments thereof described herein exhibit binding characteristics and / or biological properties as outlined for antibody MHA112, exemplified in the Examples section below. As described in the Examples section below, anti-PNAd antibody MHA112 exhibits improved binding affinity to cells expressing PNAd (Example 6) and improved ability to block T cell homing to lymph nodes (Example 4). Administration of drugs conjugated to MHA112 results in reduced tumor growth, reduced tumor metastasis and reduced tumor-draining lymph node fibrosis (Example 7), in addition to increased survival time (Example 8). Furthermore, administration of drugs conjugated to MHA112 also increased survival time in a pancreatic tumor model (Example 9).
[0093] The antibodies and antigen-binding fragments thereof may be characterized in that they comprise in their variable regions, e.g., in the binding domain, at least one complementarity determining region (CDR) of the VH and / or VL variable regions comprising any one of the amino acid sequences depicted in FIG. 5. The corresponding nucleotide sequences encoding the above identified variable regions are shown in Table 4 below. An exemplary set of CDRs of the above amino acid sequences of the VH and / or VL regions are depicted in FIG. 5 and Table 2. The corresponding framework regions of the CDRs of Table 2 are depicted in Table 3. However, as discussed below, the skilled artisan is well aware of the fact that in the case of CDR2 and CDR3, in addition or instead, CDRs whose amino acid sequences differ from those depicted in FIG. 5 by one, two, three or even more amino acids may be used.
[0094] [Table 2]
[0095] JPEG0007588080000003.jpg54153
[0096] JPEG0007588080000004.jpg122147
[0097] In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise at least one CDR comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5 and 8-10. In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise one, two, three, four, five or six CDRs comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 3-5 and 8-10 (see, e.g., Table 2).
[0098] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region (VH) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5. In some embodiments, the antibody or PNAd-binding fragment thereof comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5, and further comprises a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
[0099] In some embodiments, the antibody or PNAd-binding fragment thereof comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody or PNAd-binding fragment thereof comprises a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10, and further comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5.
[0100] In some embodiments, the antibody or antigen-binding fragment thereof described herein may comprise a VH comprising (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 3, (ii) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and (iii) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5. In some embodiments, the antibody or antigen-binding fragment thereof described herein may comprise a light chain variable region (VL) comprising (i) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 8, (ii) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and (iii) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10. In some embodiments, the antibody or PNAd-binding fragment thereof may further comprise a heavy chain variable region comprising a VH CDR1 of SEQ ID NO: 3, a VH CDR2 of SEQ ID NO: 4, and a VH CDR3 of SEQ ID NO: 5, and may further comprise a light chain variable region comprising a VL CDR1 of SEQ ID NO: 8, a VL CDR2 of SEQ ID NO: 9, and a VL CDR3 of SEQ ID NO: 10.
[0101] In some embodiments, an antibody or antigen-binding fragment thereof described herein may comprise a heavy chain variable region comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5.
[0102] In some embodiments, an antibody or antigen-binding fragment thereof described herein may comprise a light chain variable region comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10.
[0103] In some embodiments, the antibodies or antigen-binding fragments thereof described herein may comprise a heavy chain variable region comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5, and may further comprise a light chain variable region comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10.
[0104] In some embodiments, an antibody or antigen-binding fragment thereof described herein comprises a VH comprising a heavy chain framework region 1 (FR1) comprising the amino acid sequence set forth in SEQ ID NO:11, a heavy chain FR2 comprising the amino acid sequence set forth in SEQ ID NO:12, a heavy chain FR3 comprising the amino acid sequence set forth in SEQ ID NO:13, and a heavy chain FR4 comprising the amino acid sequence set forth in SEQ ID NO:14.
[0105] In some embodiments, an antibody or antigen-binding fragment thereof described herein comprises a VL comprising a light chain FR1 comprising the amino acid sequence set forth in SEQ ID NO: 15, a light chain FR2 comprising the amino acid sequence set forth in SEQ ID NO: 16, a light chain FR3 comprising the amino acid sequence set forth in SEQ ID NO: 17, and a light chain FR4 comprising the amino acid sequence set forth in SEQ ID NO: 18.
[0106] In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a VH comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5, wherein the VH has at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% sequence identity to the amino acid sequence of SEQ ID NO:2. In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a VH comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5, wherein the VH has 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid substitutions, additions or deletions relative to the amino acid sequence of SEQ ID NO:2. In some examples, the amino acid substitutions are conservative amino acid substitutions.
[0107] In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a VL comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10, wherein the VL has at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or 100% sequence identity to the amino acid sequence of SEQ ID NO:7. In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a VL comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10, wherein the VL has 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid substitutions, additions or deletions relative to the amino acid sequence of SEQ ID NO:7. In some examples, the amino acid substitutions are conservative amino acid substitutions.
[0108] In some embodiments, an antibody or antigen-binding fragment thereof described herein comprises (a) a VH comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5, wherein the VH has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:2; and (b) a VL comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10, wherein the VL has at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or 100% sequence identity to the amino acid sequence of SEQ ID NO:7. In some embodiments, the antibody or antigen-binding fragment thereof described herein comprises (a) a VH comprising a VH CDR1 comprising or consisting of SEQ ID NO:3, a VH CDR2 comprising or consisting of SEQ ID NO:4, and a VH CDR3 comprising or consisting of SEQ ID NO:5, with 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions, additions, or deletions relative to the amino acid sequence of SEQ ID NO:2; and (b) a VL comprising a VL CDR1 comprising or consisting of SEQ ID NO:8, a VL CDR2 comprising or consisting of SEQ ID NO:9, and a VL CDR3 comprising or consisting of SEQ ID NO:10, with 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid substitutions, additions, or deletions relative to the amino acid sequence of SEQ ID NO:7. In some embodiments, the substitution is a conservative substitution. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a side chain with a similar charge. Families of amino acid residues having side chains with similar charges have been defined in the art.These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0109] In some embodiments, variants of the antibodies described herein (e.g., antibodies or antigen-binding fragments thereof having amino acid substitutions, additions or deletions to the VH and / or VL of the amino acid sequences set forth in SEQ ID NOs: 2 and 7, respectively) retain the ability to bind to PNAd and / or retain one or more characteristics of antibody MHA112 described in the Examples below.
[0110] In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a heavy chain variable region (VH) that comprises or consists of the amino acid sequence of SEQ ID NO: 2. In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a light chain variable region (VL) that comprises or consists of the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments thereof described herein comprise a heavy chain variable region (VH) that comprises or consists of the amino acid sequence of SEQ ID NO: 2 and further comprise a light chain variable region (VL) that comprises or consists of the amino acid sequence of SEQ ID NO: 7. In some embodiments, the antibodies or antigen-binding fragments thereof comprise a VH of SEQ ID NO: 2 and a VL of SEQ ID NO: 7.
[0111] In some embodiments, the antibodies described herein comprise a heavy chain comprising a VH as described herein. In some examples, the heavy chain comprises an IgM constant region. In some examples, the heavy chain comprises a human IgM constant region.
[0112] In some embodiments, the antibodies described herein comprise a light chain comprising a VL as described herein. In some examples, the light chain comprises a kappa constant region. In some examples, the light chain comprises a human kappa constant region. In some examples, the light chain comprises a lambda constant region. In some examples, the light chain comprises a human lambda constant region.
[0113] In some embodiments, the antibodies described herein comprise a heavy chain comprising a VH described herein and a light chain comprising a VL described herein, wherein the heavy chain comprises an IgM (e.g., human IgM) constant region and the light chain comprises a kappa (e.g., human kappa) constant region. In some embodiments, the antibodies described herein comprise a heavy chain comprising a VH described herein and a light chain comprising a VL described herein, wherein the heavy chain comprises an IgM (e.g., human IgM) constant region and the light chain comprises a lambda (e.g., lambda kappa) constant region.
[0114] Alternatively, the antibodies described herein are antibodies or antigen-binding fragments, derivatives or variants thereof that compete for binding to PNAd with an antibody having VH CDR1-3 as set forth in SEQ ID NOs: 3-5, respectively. Alternatively, the antibodies described herein are antibodies or antigen-binding fragments, derivatives or variants thereof that compete for binding to PNAd with an antibody having VL CDR1-3 as set forth in SEQ ID NOs: 8-10, respectively. Alternatively, the antibodies described herein are antibodies or antigen-binding fragments, derivatives or variants thereof that compete for binding to PNAd with an antibody having VH CDR1-3 as set forth in SEQ ID NOs: 3-5, respectively, and VL CDR1-3 as set forth in SEQ ID NOs: 8-10, respectively. Alternatively, the antibodies described herein are antibodies or antigen-binding fragments, derivatives or variants thereof that compete for binding to PNAd with an antibody having VH and / or VL as set forth in SEQ ID NOs: 2 and 7, respectively. The antibodies may be human, rodent (e.g., murine), chimeric or humanized, particularly for therapeutic applications.
[0115] Alternatively, the antibody described herein is an antibody or antigen-binding fragment, derivative or variant thereof that binds to the same epitope as an anti-PNAd antibody comprising a VH of SEQ ID NO:2 and a VL of SEQ ID NO:7.
[0116] Competition between antibodies is determined by an assay in which the immunoglobulin under test inhibits specific binding of a reference antibody to a common antigen, such as PNAd. Many types of competitive binding assays are known, e.g., solid-phase direct or indirect radioimmunoassays (RIA), solid-phase direct or indirect enzyme immunoassays (EIA), sandwich competition assays; see Stahli et al., Methods in Enzymology 9 (1983), 242-253; solid-phase direct biotin-avidin EIA; see Kirkland et al., J. Immunol. 137 (1986), 3614-3619 and Cheung et al., Virology 176 (1990), 546-552; solid-phase direct labeling assays, solid-phase direct labeling sandwich assays; see Harlow and Lane, Antibodies, A Laboratory Manual, Cold Spring Harbor Press (1988); solid-phase direct labeling RIA using I125 label; Morel et al., Molec. Immunol. 25 (1988), See, e.g., Moldenhauer et al., Scand. J. Immunol. 32 (1990), 7-15 and Moldenhauer et al., Scand. J. Immunol. 32 (1990), 77-82. Typically, such assays involve the use of purified PNAd or aggregates thereof bound to a solid surface or cells bearing either of these, unlabeled test immunoglobulins and labeled reference immunoglobulins, i.e., human monoclonal antibodies as described herein. Competitive inhibition is measured by determining the amount of label bound to the solid surface or cells in the presence of the test immunoglobulin. Usually, the test immunoglobulin is present in excess. In some embodiments, competitive binding assays are performed under conditions as described for the ELISA assay in the accompanying examples. Antibodies identified by competitive assays (competitive antibodies) include antibodies that bind to the same epitope as the reference antibody and antibodies that bind to adjacent epitopes in sufficient proximity to cause steric hindrance to the epitope bound by the reference antibody.Typically, when a competing antibody is present in excess, it will inhibit specific binding of a reference antibody to a common antigen by at least 50% or 75%. Thus, the present invention is further drawn to an antibody or antigen-binding fragment, variant or derivative thereof, where the antibody competitively inhibits binding of a reference antibody comprising a VH of SEQ ID NO:2 and a VL of SEQ ID NO:7 to a PNAd.
[0117] In some embodiments, provided herein is an isolated polypeptide comprising an immunoglobulin heavy chain variable region (VH), wherein at least one of the VH-CDRs of the heavy chain variable region or at least two of the VH-CDRs of the heavy chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference heavy chain VH-CDR1, VH-CDR2 or VH-CDR3 amino acid sequence from an antibody disclosed herein (e.g., see Table 2 for VH CDR sequences). Alternatively, the VH-CDR1, VH-CDR2 and VH-CDR3 regions of the VH are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference heavy chain VH-CDR1, VH-CDR2 and VH-CDR3 amino acid sequence derived from an antibody disclosed herein (e.g., see Table 2 for VH CDR sequences). Thus, the heavy chain variable regions described herein can have VH-CDR1, VH-CDR2 and VH-CDR3 polypeptide sequences related to the sequences in Table 2 (i.e., SEQ ID NOs: 3-5). Table 2 shows the VH-CDRs defined by the IMGT system, however, other CDR definitions, e.g., VH-CDRs defined by the Kabat or Chothia systems, are also included in the present invention and can be readily identified by one of skill in the art using the sequences provided in Tables 2-4. In some embodiments, the amino acid sequence of the reference VH CDR1 is SEQ ID NO:3, the amino acid sequence of the reference VH CDR2 is SEQ ID NO:4, and the amino acid sequence of the reference VH CDR3 is SEQ ID NO:5.
[0118] An isolated polypeptide described herein may comprise an immunoglobulin heavy chain variable region (VH) having a polypeptide sequence in which the VH-CDR1, VH-CDR2 and VH-CDR3 regions are identical to the VH-CDR1, VH-CDR2 and VH-CDR3 sequences shown in Table 2 (i.e., SEQ ID NOs:3-5). In some embodiments, the amino acid sequence of VH CDR1 is SEQ ID NO:3, the amino acid sequence of VH CDR2 is SEQ ID NO:4 and the amino acid sequence of VH CDR3 is SEQ ID NO:5.
[0119] Further, the isolated polypeptide may comprise an immunoglobulin heavy chain variable region (VH) having a polypeptide sequence in which the VH-CDR1, VH-CDR2 and VH-CDR3 regions are identical to the VH-CDR1, VH-CDR2 and VH-CDR3 sequences shown in Table 2, except for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions in any one VH-CDR. In some embodiments, the amino acid substitutions are conservative. In some embodiments, the amino acid sequence of VH CDR1 is SEQ ID NO:3, the amino acid sequence of VH CDR2 is SEQ ID NO:4 and the amino acid sequence of VH CDR3 is SEQ ID NO:5.
[0120] The isolated polypeptide may comprise an immunoglobulin light chain variable region (VL) in which at least one of the VL-CDRs of the light chain variable region or at least two of the VL-CDRs of the light chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference light chain VL-CDR1, VL-CDR2 or VL-CDR3 amino acid sequence from an antibody disclosed herein (e.g., see Table 2 for VL CDR sequences). Alternatively, the VL-CDR1, VL-CDR2 and VL-CDR3 regions of the VL may be at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference light chain VL-CDR1, VL-CDR2 and VL-CDR3 amino acid sequence from an antibody disclosed herein (e.g., see Table 2 for VL CDR sequences). Thus, the light chain variable region may have VL-CDR1, VL-CDR2 and VL-CDR3 polypeptide sequences related to the sequences in Table 2 (i.e., SEQ ID NOs: 8-10). Table 2 shows the VL-CDRs defined by the IMGT system, however, other CDR definitions, e.g., VL-CDRs defined by the Kabat or Chothia systems, are also encompassed by the present invention. In some embodiments, the amino acid sequence of the reference VL CDR1 is SEQ ID NO: 8, the amino acid sequence of the reference VL CDR2 is SEQ ID NO: 9, and the amino acid sequence of the reference VL CDR3 is SEQ ID NO: 10.
[0121] Also provided herein is an isolated polypeptide comprising an immunoglobulin light chain variable region (VL), wherein the VL-CDR1, VL-CDR2 and VL-CDR3 regions have polypeptide sequences identical to the VL-CDR1, VL-CDR2 and VL-CDR3 sequences of Table 2. In some embodiments, the amino acid sequence of the VL CDR1 is SEQ ID NO:8, the amino acid sequence of the VL CDR2 is SEQ ID NO:9 and the amino acid sequence of the VL CDR3 is SEQ ID NO:10.
[0122] The isolated polypeptide may also comprise an immunoglobulin light chain variable region (VL) having a polypeptide sequence in which the VL-CDR1, VL-CDR2 and VL-CDR3 regions are identical to the VL-CDR1, VL-CDR2 and VL-CDR3 regions shown in Table 2, except for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions in any one VL-CDR. In some embodiments, the amino acid substitutions are conservative. In some embodiments, the amino acid sequence of the VL CDR1 is SEQ ID NO:8, the amino acid sequence of the VL CDR2 is SEQ ID NO:9 and the amino acid sequence of the VL CDR3 is SEQ ID NO:10.
[0123] The immunoglobulin or its coding cDNA may be modified. Thus, the methods described herein may include any one of the steps of generating chimeric antibodies, humanized antibodies, single chain antibodies, Fab fragments, bispecific antibodies, fusion antibodies, labeled antibodies or any one of their analogs. Corresponding methods are known to those skilled in the art and are described, for example, in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor (1988). If the antibody derivatives are obtained by phage display technology, surface plasmon resonance, as used in the BIAcore system, may be used to increase the efficiency of phage antibodies that bind to the same epitope as any one of the antibodies described herein (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13). The generation of chimeric antibodies is described, for example, in International Application WO 89 / 09622. Methods for the production of humanized antibodies are described, for example, in European application EP 0239400 and International application WO 90 / 07861. Another source of antibodies to be used according to the present invention are so-called xenogenous antibodies. The general principles for the production of xenogenous antibodies, e.g., human-like antibodies, in mice are described, for example, in International applications WO 91 / 10741, WO 94 / 02602, WO 96 / 34096 and WO 96 / 33735. As discussed above, the antibodies described herein can exist in various forms, including, for example, Fv, Fab and F(ab)2, as well as in single chains, in addition to competing antibodies; see also, for example, International application WO 88 / 09344. Antibodies produced by such methods are also provided herein.
[0124] The antibody or its corresponding immunoglobulin chain(s) described herein may be further modified using conventional techniques known in the art, for example, by amino acid deletion(s), insertion(s), substitution(s), addition(s) and / or recombination(s) and / or any other modification(s) known in the art, alone or in combination. Methods for introducing such modifications into the DNA sequence underlying the amino acid sequence of an immunoglobulin chain are well known to those skilled in the art; see, for example, Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) NY and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, NY (1994). Modifications of the antibodies described herein include chemical and / or enzymatic derivatization at one or more component amino acids, including side chain modifications, backbone modifications, and N- and C-terminal modifications, including acetylation, hydroxylation, methylation, amidation, and carbohydrate or lipid moieties, binding of cofactors, and the like. Similarly, the invention encompasses the production of chimeric proteins comprising the described antibodies or some fragments thereof at their amino termini fused at their carboxy termini to a heterologous molecule, such as an immunostimulatory ligand; see, for example, International Application WO 00 / 30680 for corresponding technical details.
[0125] Furthermore, since it is frequently observed that the heavy chain CDR3 (HCDR3) of the binding molecules described above is the region with the greater degree of variability and the predominant involvement in antigen-antibody interaction, peptides are provided herein that contain the CDR3 region of the variable region of any one of the described antibodies, particularly the CDR3 of the heavy chain. Such peptides can be easily synthesized or produced by recombinant means to produce the binding agent described herein. Such methods are well known to those skilled in the art. The peptides can be synthesized, for example, using commercially available automated peptide synthesizers. The peptides can also be produced by recombinant technology by incorporating the DNA that expresses the peptide into an expression vector and transforming cells with the expression vector to produce the peptide.
[0126] Thus, described herein are binding molecules, e.g., antibodies or binding fragments thereof, that bind to the human anti-PNAd antibodies described herein and exhibit the described properties, i.e., specifically recognize (bind) PNAd. Such antibodies and binding molecules can be tested for their binding specificity and affinity by ELISA and Western blot and immunohistochemistry as described herein, see e.g., Examples.
[0127] As an alternative to directly obtaining immunoglobulins from cultures of immortalized B cells or B memory cells, the immortalized cells described herein can be used as a source of rearranged heavy and light chain loci for subsequent expression and / or genetic engineering. The rearranged antibody genes can be reverse transcribed from the appropriate mRNA to generate cDNA. If necessary, the heavy chain constant region can be replaced with that of a different isotype or can be completely removed. The variable regions can be linked to encode a single chain Fv region. Multiple Fv regions can be linked to confer the ability to bind to two or more targets, or chimeric heavy and light chain combinations can be used. Once the genetic material is available, it is easy to design such analogs that both retain their ability to bind to the desired target. Methods for cloning antibody variable regions and producing recombinant antibodies are known to those skilled in the art and are described, for example, in Gilliland et al., Tissue Antigens 47 (1996), 1-20; Doenecke et al., Leukemia 11 (1997), 1787-1792.
[0128] Once the appropriate genetic material is obtained and modified as necessary to code for the analog, the coding sequence, including at a minimum the coding for the heavy and light chain variable regions, can be inserted into an expression system contained in a vector, which can be transfected into a standard recombinant host cell.For efficient processing, a variety of such host cells can be used, but mammalian cells can be considered.Common mammalian cell lines for this purpose include, but are not limited to, CHO cells, HEK293 cells or NSO cells.
[0129] Production of the antibody or analog is then carried out by culturing the modified recombinant host under culture conditions appropriate for host cell growth and expression of the coding sequence. The antibodies are then recovered by isolating them from the culture. The expression system is designed to include a signal peptide so that the resulting antibody is secreted into the medium, although intracellular production is also possible.
[0130] In accordance with the above, the present invention also relates to a polynucleotide encoding the antibody or equivalent binding molecule described herein.In some embodiments, the polynucleotide encodes at least the variable region of the immunoglobulin chain of the antibody.Usually, the variable region encoded by the polynucleotide comprises at least one complementarity determining region (CDR) of the VH and / or VL of the variable region of the antibody.
[0131] Those skilled in the art will easily understand that the variable domain of the antibody having the above variable domain can be used to construct other polypeptides or antibodies with desired specificity and biological function. Thus, polypeptides and antibodies are provided herein that contain at least one or more CDRs, for example all of the CDRs, of the above variable domains, and advantageously have substantially the same or similar binding characteristics as the antibodies described in the accompanying examples. Those skilled in the art will be aware that binding affinity can be enhanced by making amino acid substitutions within the CDRs or within the hypervariable loops that overlap with the CDRs as defined by Kabat (Chothia and Lesk, J. Mol. Biol. 196 (1987), 901-917); see, for example, Riechmann, et al, Nature 332 (1988), 323-327. Thus, antibodies are also provided herein in which one or more of the described CDRs contain one or more, or no more than two amino acid substitutions. In some embodiments, the antibodies described herein comprise two or all three CDRs of a variable region as shown in Table 2 in one or both of its immunoglobulin chains.
[0132] Binding molecules as known to those skilled in the art, such as antibodies or antigen-binding fragments, variants or derivatives thereof described herein, may contain a constant region, which mediates one or more effector functions. For example, binding of the C1 component of complement to an antibody constant region can activate the complement system. Complement activation is important in opsonizing and lysing cellular pathogens. Complement activation also stimulates inflammatory responses and may also be involved in autoimmune hypersensitivity. Furthermore, antibodies bind to receptors on various cells via the Fc region, and the Fc receptor binding site on the antibody Fc region binds to the Fc receptor (FcR) on the cell. There are several Fc receptors that are specific for different classes of antibodies, including IgG (gamma receptors), IgE (epsilon receptors), IgA (alpha receptors) and IgM (mu receptors). The binding of antibodies to Fc receptors on cell surfaces triggers several important and diverse biological responses, including phagocytosis and destruction of antibody-coated particles, clearance of immune complexes, lysis of antibody-coated target cells by killer cells (called antibody-dependent cell-mediated cytotoxicity or ADCC), release of inflammatory mediators, and placental crossing and control of immunoglobulin production.
[0133] Thus, some embodiments described herein include antibodies or their antigen-binding fragments, variants or derivatives, in which at least a small portion of one or more constant region domains are deleted or otherwise modified to provide desired biochemical characteristics, such as reduced effector function, ability to non-covalently dimerize, increased ability to localize at the site of PNAd, reduced serum half-life or increased serum half-life, when compared with unmodified whole antibodies of approximately the same immunogenicity.For example, some antibodies for use in the diagnostic and treatment methods described herein are domain-deleted antibodies, which comprise a polypeptide chain similar to an immunoglobulin heavy chain, but lack at least a portion of one or more heavy chain domains.For example, in certain antibodies, an entire domain of the constant region of the modified antibody is deleted, for example, all or part of the CH2 domain is deleted. In other embodiments, certain antibodies for use in the diagnostic and treatment methods described herein have constant regions, e.g., IgM heavy chain constant regions, that have been altered to eliminate glycosylation, and are referred to elsewhere herein as aglycosylated or "agri" antibodies. Such "agri" antibodies can be prepared enzymatically and by engineering consensus glycosylation site(s) in the constant region. Without wishing to be bound by theory, it is believed that "agri" antibodies may have improved safety and stability profiles in vivo. Methods for generating aglycosylated antibodies with desired effector functions can be found, for example, in International Application WO 2005 / 018572, the entire contents of which are incorporated herein by reference.
[0134] In certain antibodies or antigen-binding fragments, variants or derivatives thereof described herein, the Fc portion can be mutated to reduce effector function using techniques known in the art. For example, deletion or inactivation (by point mutation or other means) of constant region domains can reduce Fc receptor binding of circulating modified antibodies, thereby increasing PNAd localization. In other cases, constant region modifications consistent with the present invention can alleviate complement binding, thus reducing serum half-life and non-specific association of conjugated cytotoxins. Still other modifications of the constant region can be used to modify disulfide bonds or oligosaccharide moieties, which allow for enhanced localization due to increased antigen specificity or antibody mobility. The resulting physiological profile, bioavailability and other biochemical effects of modifications, such as PNAd localization, biodistribution and serum half-life, can be easily measured and quantified using well-known immunological techniques without undue experimentation.
[0135] In some of the antibodies or antigen-binding fragments, variants or derivatives described herein, the Fc portion may be mutated or replaced with alternative protein sequences to increase cellular uptake of the antibody, for example by enhancing receptor-mediated endocytosis of the antibody via Fcγ receptors, LRP or Thy1 receptors, or by "SuperAntibody Technology" that is said to allow the antibody to be delivered into living cells without damaging them (Expert Opin. Biol. Ther. (2005), 237-241). For example, the generation of bispecific or multispecific antibodies and fusion proteins of cell surface receptors with antibody binding regions and specific sequences that bind to the cognate protein ligand or PNAd of the cell surface receptor may be engineered using techniques known in the art.
[0136] In some antibodies or antigen-binding fragments, variants, or derivatives thereof described herein, the Fc portion may be mutated or exchanged with alternative protein sequences, or the antibody may be chemically modified to increase its blood-brain barrier penetration.
[0137] Modified forms of the antibody or its antigen-binding fragment, variant or derivative described herein can be made from the whole precursor or parent antibody using techniques known in the art. Exemplary techniques are discussed in more detail herein. The antibody or its antigen-binding fragment, variant or derivative described herein can be manufactured using techniques known in the art. In some embodiments, the antibody molecule or its fragment is "recombinantly produced", i.e., produced using recombinant DNA technology. Exemplary techniques for producing antibody molecules or its fragments are discussed in more detail elsewhere herein.
[0138] The antibodies or antigen-binding fragments, variants or derivatives described herein include derivatives that are modified, for example, by covalent attachment of any type of molecule to the antibody, such that the covalent attachment does not prevent the antibody from specifically binding to its cognate epitope. For example, but in no way limiting, antibody derivatives include antibodies that are modified, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protecting / blocking groups, proteolytic cleavage, linkage to cellular ligands or other proteins, etc. Any of a number of chemical modifications can be performed by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. In addition, derivatives can contain one or more non-classical amino acids.
[0139] In some embodiments, the antibodies or antigen-binding fragments, variants, or derivatives described herein will not induce a harmful immune response in the animal to be treated, e.g., in humans. In some embodiments, the binding molecules, e.g., the antibodies or antigen-binding fragments described herein, are derived from a patient, e.g., a human patient, and then used in the same species from which they were derived, e.g., humans, to reduce or minimize the occurrence of a harmful immune response.
[0140] Deimmunization may also be used to reduce the immunogenicity of antibodies. As used herein, the term "deimmunization" includes alterations of antibodies to modify T cell epitopes; see, for example, International Application Publication Nos. WO 98 / 52976 and WO 00 / 34317. For example, the VH and VL sequences obtained from the starting antibody are analyzed, and a human T cell epitope "map" obtained from each V region indicates the location of the epitopes in relation to the complementarity determining regions (CDRs) and other important residues within the sequence. Individual T cell epitopes obtained from the T cell epitope map are analyzed to identify alternative amino acid substitutions with a low risk of altering the activity of the final antibody. A variety of alternative VH and VL sequences containing combinations of amino acid substitutions are designed, and these sequences are then incorporated into various binding polypeptides, such as PNAd-specific antibodies or immunospecific fragments thereof, and then tested for function, for use in the diagnostic and treatment methods disclosed herein. Typically, between 12 and 24 variant antibodies are generated and tested. The competing heavy and light chain genes containing the modified V and human C regions are then cloned into expression vectors, and the plasmids are then introduced into cell lines for production of the whole antibody. The antibodies are then compared in appropriate biochemical and biological assays to identify the optimal variant.
[0141] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art, including the use of hybridoma, recombinant and phage display techniques or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques known in the art and including those taught in, for example, Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2nd ed. (1988); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas Elsevier, NY, 563-681 (1981), which are incorporated by reference in their entirety. The term "monoclonal antibody" as used herein is not limited to antibodies produced by hybridoma techniques. The term "monoclonal antibody" refers to an antibody derived from a single clone, including any eukaryotic, prokaryotic or phage clone, and not the method by which it is produced. Thus, the term "monoclonal antibody" is not limited to antibodies produced by hybridoma techniques.
[0142] In the well-known hybridoma process (Kohler et al., Nature 256 (1975), 495), relatively short-lived or mortal lymphocytes from a mammal, such as B cells from a murine subject as described herein, are fused with an immortal tumor cell line (e.g., a myeloma cell line), resulting in hybrid cells or "hybridomas" that are both immortal and capable of producing the genetically encoded antibodies of the B cells. The resulting hybrids are separated by selection, dilution and regrowth into monogenic strains, each individual strain containing a specific gene that forms a single antibody. They produce antibodies that are homogeneous against the desired antigen with respect to their pure genetic origin and are referred to as "monoclonal."
[0143] The hybridoma cells thus prepared are seeded and grown in a suitable culture medium containing one or more substances that inhibit the growth or survival of unfused, parental myeloma cells.Those skilled in the art will understand that the reagents, cell lines and culture media for the formation, selection and growth of hybridomas are commercially available from several sources, and standardized protocols are well established.Generally, the culture medium in which the hybridoma cells are growing is assayed for the production of monoclonal antibodies against desired antigens.The binding specificity of the monoclonal antibodies produced by hybridoma cells is determined by in vitro assays, such as immunoprecipitation, radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA) as described herein. After hybridoma cells which produce antibodies of the desired specificity, affinity and / or activity are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods; see, e.g., Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, pp 59-103 (1986). It will further be understood that the monoclonal antibodies secreted by the subclones can be separated from the culture medium, ascites fluid, or serum by conventional purification procedures, such as, for example, protein A, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[0144] In some embodiments, lymphocytes can be selected by micromanipulation and variable genes can be isolated. For example, peripheral blood mononuclear cells can be isolated from immunized or naturally immune mammals, e.g., humans, and cultured in vitro for about 7 days. The cultures can be screened for specific immunoglobulins that meet screening criteria. Cells can be isolated from positive wells. Individual Ig-producing B cells can be isolated by FACS or by identifying them in a complement-mediated hemolytic plaque assay. Ig-producing B cells can be micromanipulated into a tube and the VH and VL genes can be amplified, e.g., using RT-PCR. The VH and VL genes can be cloned into an antibody expression vector and transfected into cells (e.g., eukaryotic or prokaryotic cells) for expression.
[0145] Alternatively, antibody-producing cell lines can be selected and cultured using techniques well known to those skilled in the art. Such techniques are described in various laboratory manuals and major publications. In this regard, suitable techniques for use in the methods and compositions described below are described in Current Protocols in Immunology, Coligan et al., Eds., Green Publishing Associates and Wiley-Interscience, John Wiley and Sons, New York (1991), the entire text of which, including appendix, is incorporated herein by reference.
[0146] Antibody fragments that recognize specific epitopes can be produced by known techniques. For example, Fab and F(ab')2 fragments can be produced by recombinant or by proteolytic cleavage of immunoglobulin molecules using enzymes such as papain (resulting in Fab fragments) or pepsin (resulting in F(ab')2 fragments). F(ab')2 fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain. Such fragments are sufficient to be used, for example, in immunodiagnostic procedures involving coupling the immunospecific portion of the immunoglobulin to a detection reagent, such as a radioisotope.
[0147] In some embodiments, the antibodies described herein comprise at least one heavy or light chain CDR of an antibody molecule. In another embodiment, the antibodies described herein comprise at least two CDRs from one or more antibody molecules. In another embodiment, the antibodies described herein comprise at least three CDRs from one or more antibody molecules. In another embodiment, the antibodies described herein comprise at least four CDRs from one or more antibody molecules. In another embodiment, the antibodies described herein comprise at least five CDRs from one or more antibody molecules. In another embodiment, the antibodies described herein comprise at least six CDRs from one or more antibody molecules. Exemplary antibody molecules comprising at least one CDR that may be included in a subject antibody are described herein.
[0148] The antibodies described herein can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or by recombinant expression techniques as described herein.
[0149] In some embodiments, the antibodies or antigen-binding fragments, variants or derivatives described herein comprise synthetic constant regions in which one or more domains have been partially or completely deleted ("domain deleted antibodies"). In some embodiments, the corresponding modified antibodies will comprise domain deleted constructs or variants in which the entire CH2 domain has been removed. For other embodiments, a short connecting peptide may be substituted for the deleted domain to provide flexibility and freedom of movement of the variable region. Those skilled in the art will appreciate that such constructs are particularly preferred due to the regulatory properties of the CH2 domain on the catabolic rate of the antibody. Domain deleted constructs can be derived using vectors encoding IgG1 human constant domains, see for example International Application WO 02 / 060955 and WO 02 / 096948. This vector is engineered to delete the CH2 domain and provide a synthetic vector expressing a domain deleted IgG1 constant region.
[0150] In some embodiments, the antibody or antigen-binding fragment, variant or derivative described herein is a minibody. Minibodies can be produced using methods described in the art, see, for example, U.S. Patent No. 5,837,821 or International Application WO 94 / 09817.
[0151] In some embodiments, the antibodies or antigen-binding fragments, variants or derivatives described herein include immunoglobulin heavy chains with deletions or substitutions of two, three or even a single amino acid, so long as they allow association between monomeric subunits and retain binding to PNAd. For example, mutation of a single amino acid in a selected stretch of the CH2 domain may be sufficient to substantially reduce Fc binding and thereby increase PNAd localization. Similarly, it may be desirable to simply delete a portion of one or more constant region domains that control the effector function to be modulated (e.g., complement binding). Such partial deletion of the constant region may improve selected characteristics of the antibody (serum half-life) while leaving other desirable functions associated with the constant region domain of interest intact. Furthermore, as mentioned above, the constant regions of the disclosed antibodies may be synthetic with mutations or substitutions of one or more amino acids that enhance the profile of the resulting construct. In this regard, it may be possible to disrupt the activity provided by a conserved binding site (e.g., Fc binding) while substantially maintaining the configuration and immunogenicity profile of the modified antibody. Still other embodiments include the addition of one or more amino acids to the constant region to provide a desirable characteristic, such as enhancing effector function or providing more cytotoxin or carbohydrate binding, In such embodiments, it may be desirable to insert or duplicate a particular sequence from a selected constant region domain.
[0152] The present invention also provides antibodies comprising, consisting essentially of, or consisting of variants (including derivatives) of the antibody molecules (e.g., VH and / or VL regions) described herein, wherein the antibodies or fragments thereof immunospecifically bind to PNAd. Standard techniques known to those skilled in the art can be used to introduce mutations into the nucleotide sequence encoding the antibody, including but not limited to site-directed mutagenesis and PCR-mediated mutagenesis, which result in amino acid substitutions. In some embodiments, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the reference VH region, VH-CDR1, VH-CDR2, VH-CDR3, VL region, VL-CDR1, VL-CDR2, or VL-CDR3. Alternatively, mutations can be introduced randomly along all or part of the coding sequence, e.g., by saturation mutagenesis, and the resulting mutants can be screened for biological activity to identify mutants that retain activity (e.g., the ability to bind PNAd).
[0153] For example, it is possible to introduce mutations only in the framework regions or only in the CDR regions of an antibody molecule. The introduced mutations can be silent or neutral missense mutations, e.g., have no or little effect on the ability of the antibody to bind to antigen; in fact, some such mutations do not change the amino acid sequence in any way. These types of mutations can be useful for optimizing codon usage or improving the antibody production of hybridomas. Codon-optimized coding regions that code for the antibodies described herein are disclosed elsewhere herein. Alternatively, non-neutral missense mutations can change the ability of the antibody to bind to antigen. Although not essential, the location of most silent and neutral missense mutations is likely to be in the framework regions, and the location of most non-neutral missense mutations is likely to be in the CDRs. A person skilled in the art will be able to design and test mutant molecules with desired properties, e.g., without alteration of antigen binding activity or alteration of binding activity (e.g., improved antigen binding activity or change of antibody specificity). Following mutagenesis, the encoded protein can be routinely expressed and the functional and / or biological activity of the encoded protein (e.g., the ability to immunospecifically bind at least one epitope of a PNAd) can be determined using the techniques described herein or by routine modification techniques known in the art.
[0154] PNAd-binding substances, such as, but not limited to, the PNAd-binding antibodies described herein, can be characterized using any in vivo or in vitro model. Those skilled in the art will readily understand that the PNAd-binding substances (e.g., antibodies) described herein can be characterized in the mouse model described herein.
[0155] III. Polynucleotides Encoding Antibodies Also provided herein is a polynucleotide that encodes the antibody or its antigen-binding fragment, variant or derivative described herein. The polynucleotide that encodes the antibody or its antigen-binding fragment, variant or derivative can be composed of any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. For example, the polynucleotide that encodes the antibody or its antigen-binding fragment, variant or derivative can be composed of single-stranded and double-stranded DNA, DNA that is a mixture of single-stranded and double-stranded regions, single-stranded and double-stranded RNA and RNA that is a mixture of single-stranded and double-stranded regions, hybrid molecules that include DNA and RNA that can be single-stranded or, more usually, double-stranded or a mixture of single-stranded and double-stranded regions. Furthermore, the polynucleotide that encodes the antibody or its antigen-binding fragment, variant or derivative can be composed of a triple-stranded region that includes RNA or DNA or both RNA and DNA. The polynucleotide that encodes the antibody or its antigen-binding fragment, variant or derivative can also contain one or more modified bases or DNA or RNA backbones that are modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.
[0156] An isolated polynucleotide encoding a non-naturally occurring variant of a polypeptide derived from an immunoglobulin (e.g., an immunoglobulin heavy or light chain portion) can be generated by introducing one or more nucleotide substitutions, additions, or deletions into the nucleotide sequence of the immunoglobulin, such that one or more amino acid substitutions, additions, or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. In some embodiments, conservative amino acid substitutions are made at one or more non-essential amino acid residues.
[0157] As is well known, RNA can be isolated from original B cells, hybridoma cells, or other transformed cells by standard techniques, such as guanidinium isothiocyanate extraction and precipitation followed by centrifugation or chromatography. If desired, mRNA can be isolated from total RNA by standard techniques, such as chromatography on oligo-dT cellulose. Suitable techniques are well known in the art. In some embodiments, cDNAs encoding the light and heavy chains of the antibody can be made simultaneously or separately using reverse transcriptase and DNA polymerase according to well-known methods. PCR can be initiated by consensus constant region primers or by more specific primers based on published heavy and light chain DNA and amino acid sequences. As discussed above, PCR can also be used to isolate DNA clones encoding antibody light and heavy chains. In this case, the library can be screened by consensus primers or larger homologous probes, such as human constant region probes.
[0158] DNA, usually plasmid DNA, can be isolated from cells using techniques known in the art and restriction mapped and sequenced according to standard, well-known techniques, for example as detailed in the aforementioned references relating to recombinant DNA technology. Of course, DNA can be synthesized according to the present invention at any point during the isolation process or subsequent analysis.
[0159] In some embodiments, an isolated polynucleotide is provided herein that comprises, consists essentially of, or consists of a nucleic acid encoding an immunoglobulin heavy chain variable region (VH), wherein at least one of the CDRs of the heavy chain variable region or at least two of the VH-CDRs of the heavy chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference heavy chain VH-CDR1, VH-CDR2 or VH-CDR3 amino acid sequence from an antibody disclosed herein. Alternatively, the VH-CDR1, VH-CDR2 or VH-CDR3 region of the VH is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference heavy chain VH-CDR1, VH-CDR2 and VH-CDR3 amino acid sequence from an antibody disclosed herein. Thus, according to this embodiment, the heavy chain variable region of an antibody or antigen-binding fragment thereof described herein has a VH-CDR1, VH-CDR2 or VH-CDR3 polypeptide sequence related to the polypeptide sequence shown in Figure 5. In some embodiments, the amino acid sequence of the reference VH CDR1 is SEQ ID NO:3, the amino acid sequence of the reference VH CDR2 is SEQ ID NO:4, and the amino acid sequence of the reference VH CDR3 is SEQ ID NO:5.
[0160] In some embodiments, provided herein is an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region (VH), wherein the VH-CDR1, VH-CDR2 and VH-CDR3 regions have a polypeptide sequence identical to the VH-CDR1, VH-CDR2 and VH-CDR3 group shown in Figure 5, except for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions in any one VH-CDR. In some embodiments, the amino acid substitutions are conservative. In some embodiments, the amino acid sequence of VH CDR1 is SEQ ID NO:3, the amino acid sequence of VH CDR2 is SEQ ID NO:4, and the amino acid sequence of VH CDR3 is SEQ ID NO:5.
[0161] In another embodiment, an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region (VL) is provided herein, wherein at least one of the VL-CDRs of the light chain variable region or at least two of the VL-CDRs of the light chain variable region are at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference light chain VL-CDR1, VL-CDR2 or VL-CDR3 amino acid sequence from an antibody disclosed herein. Alternatively, the VL-CDR1, VL-CDR2 or VL-CDR3 region of the VL is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference light chain VL-CDR1, VL-CDR2 and VL-CDR3 amino acid sequence from an antibody disclosed herein. Thus, according to this embodiment, the light chain variable region of an antibody or antigen-binding fragment thereof described herein has a VL-CDR1, VL-CDR2 or VL-CDR3 polypeptide sequence related to the polypeptide sequence shown in Figure 5. In some embodiments, the amino acid sequence of the reference VL CDR1 is SEQ ID NO:8, the amino acid sequence of the reference VL CDR2 is SEQ ID NO:9, and the amino acid sequence of the reference VL CDR3 is SEQ ID NO:10.
[0162] In another embodiment, provided herein is an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region (VL), wherein the VL-CDR1, VL-CDR2 and VL-CDR3 regions have a polypeptide sequence identical to the VL-CDR1, VL-CDR2 and VL-CDR3 group shown in Figure 5, except for 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions in any one VL-CDR. In some embodiments, the amino acid substitutions are conservative. In some embodiments, the amino acid sequence of the VL CDR1 is SEQ ID NO:8, the amino acid sequence of the VL CDR2 is SEQ ID NO:9, and the amino acid sequence of the VL CDR3 is SEQ ID NO:10.
[0163] In another embodiment, provided herein is an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region (VH), wherein the VH-CDR1, VH-CDR2 and VH-CDR3 regions have polypeptide sequences identical to the VH-CDR1, VH-CDR2 and VH-CDR3 groups depicted in Figure 5. In some embodiments, the amino acid sequence of VH CDR1 comprises SEQ ID NO:3, the amino acid sequence of VH CDR2 comprises SEQ ID NO:4 and the amino acid sequence of VH CDR3 comprises SEQ ID NO:5. In some embodiments, the amino acid sequence of VH CDR1 consists of SEQ ID NO:3, the amino acid sequence of VH CDR2 consists of SEQ ID NO:4 and the amino acid sequence of VH CDR3 consists of SEQ ID NO:5.
[0164] In another embodiment, provided herein is an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain variable region (VL), wherein the VL-CDR1, VL-CDR2 and VL-CDR3 regions have polypeptide sequences identical to the VL-CDR1, VL-CDR2 and VL-CDR3 groups depicted in Figure 5. In some embodiments, the amino acid sequence of VL CDR1 is SEQ ID NO:8, the amino acid sequence of VL CDR2 is SEQ ID NO:9 and the amino acid sequence of VL CDR3 is SEQ ID NO:10. In some embodiments, the amino acid sequence of VL CDR1 consists of SEQ ID NO:8, the amino acid sequence of VL CDR2 consists of SEQ ID NO:9 and the amino acid sequence of VL CDR3 consists of SEQ ID NO:10.
[0165] As known in the art, the "sequence identity" between two polypeptides or two polynucleotides is determined by comparing the amino acid or nucleic acid sequence of one polypeptide or polynucleotide to the sequence of a second polypeptide or polynucleotide.As discussed herein, whether any particular polypeptide is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% identical to another polypeptide can be determined using methods and computer programs / software known in the art, such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). BESTFIT uses the local homology algorithm of Smith and Waterman, Advances in Applied Mathematics 2 (1981), 482-489 to find the best segment of homology between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence described herein (e.g., an antibody or antigen-binding fragment thereof described herein), the percentage of identity is, of course, calculated over the entire length of the reference polypeptide sequence, with parameters set to allow for a homology gap of up to 5% of the total number of amino acids in the reference sequence.
[0166] In some embodiments, the polynucleotide comprises, consists essentially of, or consists of a nucleic acid having a polynucleotide sequence of the VH or VL region of an anti-PNAd antibody as depicted in Table 4. In this regard, one of skill in the art will readily appreciate that a polynucleotide encoding at least the variable domain of the light and / or heavy chain may encode the variable domain of both immunoglobulin chains or only one of them. Further provided herein are polynucleotides that comprise or consist of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2 (e.g., the nucleotide sequence of SEQ ID NO:1) and / or SEQ ID NO:7 (e.g., the nucleotide sequence of SEQ ID NO:6). In a specific embodiment, provided herein are polynucleotides that comprise or consist of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2 (e.g., the nucleotide sequence of SEQ ID NO:1). In another specific embodiment, provided herein are polynucleotides that comprise or consist of a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:7 (e.g., the nucleotide sequence of SEQ ID NO:6).
[0167] In some embodiments, provided herein is an isolated polynucleotide comprising, consisting essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain variable region that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or 95% identical to a reference heavy chain VH. In some embodiments, the amino acid sequence of the reference heavy chain variable region is SEQ ID NO:2.
[0168] In some embodiments, an isolated polynucleotide is provided herein that comprises, consists essentially of, or consists of a nucleic acid encoding an immunoglobulin light chain variable region that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or 95% identical to a reference light chain VL. In some embodiments, the amino acid sequence of the reference light chain variable region is SEQ ID NO:7.
[0169] Also provided herein are fragments of the polynucleotides described herein, as described elsewhere. Additionally, polynucleotides encoding fusion polynucleotides, Fab fragments and other derivatives as described herein are also contemplated.
[0170] Polynucleotides can be generated or manufactured by any method known in the art. For example, if the nucleotide sequence of an antibody is known, a polynucleotide encoding the antibody can be assembled from chemically synthesized oligonucleotides, for example, as described in Kutmeier et al., BioTechniques 17 (1994), 242, which briefly involves synthesizing overlapping oligonucleotides containing portions of the antibody-encoding sequence, annealing and ligating the oligonucleotides, and then amplifying the ligated oligonucleotides by PCR.
[0171] Alternatively, a polynucleotide encoding an antibody or an antigen-binding fragment, variant, or derivative thereof can be generated from a nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is known, the nucleic acid encoding the antibody can be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library or a cDNA library generated from any tissue or cell expressing a PNAd-specific antibody, e.g., a hybridoma cell selected to express an antibody, or a nucleic acid isolated therefrom, preferably polyA+ RNA) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence, or by cloning using an oligonucleotide probe specific for a particular gene sequence, for example, to identify a cDNA clone from a cDNA library encoding the antibody. The amplified nucleic acid generated by PCR can then be cloned into a replicable cloning vector using any method known in the art.
[0172] Once the nucleotide sequence and corresponding amino acid sequence of an antibody or antigen-binding fragment, variant, or derivative thereof has been determined, the nucleotide sequence can be manipulated using methods well known in the art for the manipulation of nucleotide sequences, such as recombinant DNA techniques, site-directed mutagenesis, PCR, etc. (see, e.g., the techniques described in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1990) and Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley & Sons, NY (1998), both of which are incorporated by reference in their entireties) to generate antibodies having different amino acid sequences, e.g., to create amino acid substitutions, deletions, and / or insertions.
[0173] IV. Expression of Antibody Polypeptides After manipulation of the isolated genetic material to provide the antibody or antigen-binding fragment, variant or derivative thereof described herein, the polynucleotide encoding the antibody is usually inserted into an expression vector for introduction into a host cell that can be used to generate the desired amount of antibody. The recombinant expression of an antibody or a fragment, derivative or analog thereof, such as a heavy or light chain of an antibody that binds to a target molecule, is described herein. Once a polynucleotide encoding an antibody molecule described herein or an antibody heavy or light chain or a portion thereof (preferably containing a heavy or light chain variable domain) is obtained, a vector for the production of the antibody molecule can be generated by recombinant DNA technology using techniques well known in the art. Thus, methods of preparing a protein by expressing a polynucleotide containing an antibody-encoding nucleotide sequence are described herein. Methods well known to those skilled in the art can be used to construct expression vectors containing the antibody coding sequence and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques and in vivo genetic recombination. Thus, the present specification provides a replicable vector that comprises the nucleotide sequence encoding the antibody molecule described herein or its antigen-binding fragment or its heavy or light chain or heavy or light chain variable domain, which is operably linked to promoter.Such vector may comprise the nucleotide sequence encoding the constant region of antibody molecule (see, for example, International Application Publication No. WO 86 / 05807 and WO 89 / 01036 and US Patent No. 5,122,464), and the variable domain of antibody can be cloned into such vector for expressing the whole heavy or light chain.
[0174] The term "vector" or "expression vector" is used herein to mean a vector used according to the methods described herein as a vehicle for introducing and expressing a desired gene into a host cell. As known to those skilled in the art, such vectors can be easily selected from the group consisting of plasmids, phages, viruses and retroviruses. In general, the vectors described herein include a selection marker, appropriate restriction sites to facilitate cloning of the desired gene and the ability to enter and / or replicate in eukaryotic or prokaryotic cells. Numerous expression vector systems can be used. For example, one class of vectors utilizes DNA elements derived from animal viruses, such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia virus, baculovirus, retrovirus (RSV, MMTV or MOMLV) or SV40 virus. Others include the use of polycistronic systems with internal ribosome binding sites. Additionally, cells in which the DNA has been integrated into their chromosomes can be selected by introducing one or more markers that allow for the selection of transfected host cells. The marker may provide prototrophy to an auxotrophic host, biocide resistance (e.g., antibiotics) or resistance to heavy metals, such as copper. The selectable marker gene may be directly linked to the DNA sequence to be expressed or introduced into the same cell by cotransformation. Additional elements may also be required for optimal synthesis of mRNA. These elements may include signal sequences, splice signals, and transcriptional promoters, enhancers, and termination signals.
[0175] In certain embodiments, the cloned variable region genes are inserted into an expression vector together with heavy and light chain constant region genes (e.g., human heavy and light chain constant region genes) as discussed above. Any expression vector capable of inducing expression in eukaryotic cells may be used. Examples of suitable vectors include, but are not limited to, the plasmids pcDNA3, pHCMV / Zeo, pCR3.1, pEF1 / His, pIND / GS, pRc / HCMV2, pSV40 / Zeo2, pTRACER-HCMV, pUB6 / V5-His, pVAX1 and pZeoSV2 (available from Invitrogen, San Diego, Calif.) and the plasmid pCI (available from Promega, Madison, Wis.). In general, in the case of immunoglobulin heavy and light chains, screening a large number of transformed cells for those expressing appropriately high levels is routine experimentation that can be performed, for example, by robotic systems. A vector system is also taught in U.S. Patent Nos. 5,736,137 and 5,658,570, each of which is incorporated herein by reference in its entirety. This system provides high expression levels, e.g., >30 pg / cell / day. Other exemplary vector systems are disclosed, for example, in U.S. Patent No. 6,413,777.
[0176] In other embodiments, the antibodies or antigen-binding fragments, variants or derivatives described herein can be expressed using polycistronic constructs, such as those described in US Patent Publication No. 2003-0157641, the entirety of which is incorporated herein. In these expression systems, multiple gene products of interest, such as heavy and light chains of antibodies, can be produced from a single polycistronic construct. These systems advantageously use internal ribosome entry sites (IRES) to provide relatively high levels of antibodies. Suitable IRES sequences are disclosed in US Patent No. 6,193,980, the entirety of which is incorporated herein. Those skilled in the art will understand that such expression systems can be used to efficiently produce the full range of antibodies disclosed herein.
[0177] More generally, once the vector or DNA sequence encoding the monomeric subunits of an antibody has been prepared, the expression vector can be introduced into a suitable host cell. Introduction of the plasmid into the host cell can be accomplished by a variety of techniques well known to those skilled in the art. These include, but are not limited to, transfection, including lipotransfection using, for example, Fugene® or Lipofectamine, protoplast fusion, calcium phosphate precipitation, cell fusion using enveloped DNA, microinjection, and infection using intact viruses. Usually, the plasmid is introduced into the host by standard calcium phosphate co-precipitation methods. The host cells carrying the expression construct are grown under conditions appropriate for light and heavy chain production, and assayed for heavy and / or light chain protein synthesis. Exemplary assay techniques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), or fluorescence-activated cell sorter analysis (FACS), immunohistochemistry, and the like.
[0178] The expression vector is transferred into a host cell by conventional techniques, and the transfected cells are then cultured by conventional techniques to produce antibodies for use in the methods described herein.Therefore, also provided herein is a host cell that contains a polynucleotide encoding the antibody or antigen-binding fragment thereof described herein, or its heavy or light chain, operably linked to a heterologous promoter.In certain embodiments, for the expression of a double-chain antibody, vectors encoding both the heavy and light chains can be co-expressed in a host cell for the expression of the entire immunoglobulin molecule, as detailed below.
[0179] A host cell can be co-transfected with two expression vectors described herein, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors can contain the same selection markers that allow for equal expression of heavy and light chain polypeptides. Alternatively, a single vector encoding both heavy and light chain polypeptides can be used. In this situation, the light chain is advantageously placed before the heavy chain to avoid excess toxic free heavy chain; see Proudfoot, Nature 322 (1986), 52; Kohler, Proc. Natl. Acad. Sci. USA 77 (1980), 2197. The coding sequences of the heavy and light chains can comprise cDNA or genomic DNA.
[0180] As used herein, "host cell" refers to a cell that has a vector constructed using recombinant DNA technology and that encodes at least one heterologous gene. In the description of the process of isolating antibodies from recombinant hosts, the terms "cell" and "cell culture" are used interchangeably to represent the source of the antibody, unless otherwise specified. In other words, recovery of polypeptide from "cell" can mean either from the whole cells that are spun down, or from the cell culture that contains both the medium and the suspended cells.
[0181] A variety of host-expression vector systems can be utilized to express antibody molecules for use in the methods described herein. Such host-expression systems represent not only the vehicle in which a coding sequence of interest may be produced and subsequently purified, but also cells that, when transformed or transfected with the appropriate nucleotide coding sequence, may express the antibody molecules described herein in situ. These include, but are not limited to, microorganisms, such as bacteria (e.g., Escherichia coli (E. coli), Bacillus subtilis (B. subtilis)) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences. subtilis); yeast (e.g., Saccharomyces, Pichia) transformed with a recombinant yeast expression vector containing the antibody coding sequence; an insect cell system infected with a recombinant viral expression vector (e.g., baculovirus) containing the antibody coding sequence; a plant cell system infected with a recombinant viral expression vector (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with a recombinant plasmid expression vector (e.g., Ti plasmid) containing the antibody coding sequence; or a mammalian cell system (e.g., COS, CHO, NSO, BLK, 293, 3T3 cells) harboring a recombinant expression construct containing a promoter derived from the genome of a mammalian cell (e.g., metallothionein promoter) or a promoter derived from the genome of a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter). In some embodiments, bacterial cells such as E. coli, and more preferably, eukaryotic cells, are used for the expression of a recombinant antibody molecule, particularly for the expression of the whole recombinant antibody molecule. For example, mammalian cells, such as Chinese hamster ovary (CHO) cells in conjunction with vectors such as the major intermediate-early gene promoter element from human cytomegalovirus, are effective expression systems for antibodies; see, e.g., Foecking et al., Gene 45 (1986), 101; Cockett et al., Bio / Technology 8 (1990), 2.
[0182] Host cell lines used for protein expression are often of mammalian origin, and those skilled in the art will be able to determine the specific host cell line that is best suited for the desired gene product to be expressed therein.Exemplary host cell lines include, but are not limited to, CHO (Chinese hamster ovary), DG44 and DUXB11 (Chinese hamster ovary line, DHFR minus), HELA (human cervical carcinoma), CVI (monkey kidney line), COS (derivative of CVI with SV40 T antigen), VERY, BHK (baby hamster kidney), MDCK, WI38, R1610 (Chinese hamster fibroblast), BALBC / 3T3 (mouse fibroblast), HAK (hamster kidney line), SP2 / O (mouse myeloma), P3x63-Ag3.653 (mouse myeloma), BFA-1c1BPT (bovine endothelial cell), RAJI (human lymphocyte) and 293 (human kidney). In specific embodiments, the host cell line is CHO or 293 cells. Host cell lines are generally available from commercial services, the American Tissue Culture Collection, or from published literature.
[0183] Furthermore, a host cell line can be selected that modulates the expression of the inserted sequence or modifies and processes the gene product in a desired specific manner. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for the function of the protein. Various host cells have characteristic specific mechanisms for post-translational processing and modification of proteins and gene products. To ensure the correct modification and processing of expressed foreign proteins, an appropriate cell line or host system can be selected. For this purpose, eukaryotic host cells can be used that have the cellular machinery for proper processing of the primary transcript, glycosylation and phosphorylation of the gene product.
[0184] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines can be engineered that stably express an antibody molecule. Rather than using an expression vector containing a viral origin of replication, a host cell can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.) and a selection marker. After introduction of the foreign DNA, the engineered cells may be allowed to grow in enriched medium for 1-2 days and then switched to selective medium. The selection marker in the recombinant plasmid confers resistance to selection, allowing the cells to stably integrate the plasmid into their chromosomes and grow to form foci that can then be cloned and expanded into cell lines. This method can be advantageously used to engineer cell lines that stably express an antibody molecule.
[0185] Several selection systems can be used, including, but not limited to, herpes simplex virus thymidine kinase (Wigler et al., Cell 11 (1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48 (1992), 202) and adenine phosphoribosyltransferase (Lowy et al., Cell 22 (1980), 817) genes, which can be used in tk-, hgprt- or aprt-cells, respectively. In addition, antimetabolite resistance is associated with the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77 (1980), 357; O'Hare et al., Proc. Natl. Acad. Sci. USA 78 (1981), 1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78 (1981), 2072); neo, which confers resistance to the aminoglycoside G-418 (Goldspiel et al., Clinical Pharmacy 12 (1993), 488-505; Wu and Wu, Biotherapy 3 (1991), 87-95; Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32 (1993), 573-596; Mulligan, Science 260 (1993), 926-932; and Morgan and Anderson, Ann. Rev. Biochem. 62 (1993), 191-217; TIB TECH 11 (1993), 155-215; and hygro (Santerre et al., Gene 30 (1984), 147), which confers resistance to hygromycin.Methods commonly known in the art of recombinant DNA technology that can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990), and in Chapters 12 and 13, Dracopoli et al. (eds), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol. 150:1 (1981), the entireties of which are incorporated herein by reference.
[0186] The expression level of antibody molecules can be increased by vector amplification; for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Academic Press, New York, Vol. 3. (1987). If the marker in the antibody expression vector system is amplifiable, increasing the level of inhibitor present in the host cell culture will increase the copy number of the marker gene. Since the amplified region is associated with the antibody gene, antibody production will also increase; see Crouse et al., Mol. Cell. Biol. 3 (1983), 257.
[0187] In vitro production allows for scale-up to provide large amounts of the desired polypeptide. Techniques for mammalian cell culture under tissue culture conditions are known in the art, including homogeneous suspension culture in, for example, airlift reactors or continuous stirrer reactors, or immobilized or entrapped cell cultures, for example, in hollow fibers, microcapsules, on agarose microbeads or ceramic cartridges. If necessary and / or desired, for example, after the preferential biosynthesis of synthetic hinge region polypeptides as described herein, or prior to or following the HIC chromatography step, the solution of the polypeptide can be purified by conventional chromatographic methods, such as gel filtration, ion exchange chromatography, chromatography on DEAE-cellulose or (immuno-) affinity chromatography.
[0188] Genes encoding the antibodies or antigen-binding fragments, variants or derivatives thereof described herein can also be expressed in non-mammalian cells, such as bacteria or insect or yeast or plant cells. Bacteria that readily take up nucleic acids include members of the enterobacteriaceae family, such as Escherichia coli or Salmonella; Bacillaceae, such as strains of Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. It will be further understood that when expressed in bacteria, the heterologous polypeptide will usually become part of inclusion bodies. The heterologous polypeptide must be isolated, purified and then assembled into a functional molecule. If a tetravalent form of the antibody is desired, the subunits will then self-assemble into a tetravalent antibody; see, for example, International Application WO 02 / 096948.
[0189] In bacterial systems, several expression vectors may be advantageously selected depending on the intended use for the antibody molecule being expressed. For example, vectors directing the expression of high levels of fusion protein products that are easily purified may be desirable when large quantities of such proteins are to be produced for the generation of pharmaceutical compositions of the antibody molecule. Such vectors include, but are not limited to, the E. coli expression vector pUR278 (Ruther et al., EMBO J. 2 (1983), 1791), pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13 (1985), 3101-3109; Van Heeke & Schuster, J. Biol. Chem. 24 (1989), 5503-5509), and the like, in which antibody coding sequences may be separately ligated into the vector in frame with the lacZ coding region to produce a fusion protein. pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). Generally, such fusion proteins are soluble and can be easily purified from lysed cells by adsorption and binding to a matrix of glutathione-agarose beads, followed by elution in the presence of free glutathione. pGEX vectors are designed to contain thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.
[0190] In addition to prokaryotes, eukaryotic microorganisms can also be used. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic microorganisms, although several other strains, e.g., Pichia pastoris, are also commonly available. For expression in Saccharomyces, the plasmid YRp7, e.g. (Stinchcomb et al., Nature 282 (1979), 39; Kingsman et al., Gene 7 (1979), 141; Tschemper et al., Gene 10 (1980), 157), is often used. This plasmid already contains the TRP1 gene, which provides a selection marker for mutant strains of yeast lacking the ability to grow on tryptophan, e.g., ATCC No. 44076 or PEP4-1 (Jones, Genetics 85 (1977), 12). The presence of the trpl lesion as a feature of the yeast host cell genome then provides an effective environment for detection of transformation by growth in the absence of tryptophan.
[0191] In an insect system, Autographa californica nuclear polyhedrosis virus (AcNPV) is commonly used as a vector to express foreign genes. The virus is grown in Spodoptera frugiperda cells. The antibody coding sequence can be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).
[0192] Once the antibodies described herein have been recombinantly expressed, the whole antibody, its dimers, individual light and heavy chains, or other immunoglobulin forms described herein can be purified according to standard procedures in the art, including, for example, by chromatography (e.g., ion exchange, affinity, particularly affinity for specific antigens following protein A, and sizing column chromatography), centrifugation, differential solubility, e.g., by ammonium sulfate precipitation, or any other standard technique for purification of proteins; see, e.g., Scopes, "Protein Purification", Springer Verlag, NY (1982). Alternatively, another method for increasing the affinity of the antibodies described herein is disclosed in US Patent Application Publication No. 2002 / 0123057.
[0193] V. Fusion Proteins and Conjugates In some embodiments, antibody polypeptide comprises one or more parts that are not normally associated with an amino acid sequence or antibody.Exemplary modifications are described in more detail below.For example, the single chain fv antibody fragment described herein can comprise a flexible linker sequence or can be modified to add a functional moiety (e.g., PEG, a drug, a toxin, or a fluorescent, radioactive, enzymatic, nuclear magnetic, heavy metal, etc. label, etc.).
[0194] The antibody polypeptide described herein can comprise, consist essentially of, or consist of fusion protein.Fusion protein is, for example, a chimeric molecule that comprises an immunoglobulin PNAd binding domain with at least one target binding site and at least one heterologous part, i.e., a part that is not naturally linked in nature.Amino acid sequences that normally exist in separate proteins that are combined in fusion polypeptide, or that normally exist in the same protein, are positioned in a new arrangement in fusion polypeptide.Fusion protein can be produced, for example, by chemical synthesis, or by producing and translating a polynucleotide that encodes peptide regions in the desired relationship.
[0195] The term "heterologous" as applied to a polynucleotide or polypeptide means that the polynucleotide or polypeptide is derived from a separate entity from the rest of the entity to which it is being compared. For example, as used herein, a "heterologous polypeptide" to be fused to an antibody or antigen-binding fragment, variant, or analog thereof is derived from a non-immunoglobulin polypeptide of the same species or an immunoglobulin or non-immunoglobulin polypeptide of a different species.
[0196] As discussed in more detail elsewhere herein, the antibody or its antigen-binding fragment, variant or derivative described herein can be further recombinantly fused to heterologous polypeptide at N-terminus or C-terminus, or can be chemically conjugated to polypeptide or other composition (including covalent and non-covalent conjugation).For example, antibody can be recombinantly fused or conjugated to molecules that are useful as labels in detection assays and effector molecules, such as heterologous polypeptides, drugs, radionuclides or toxins; for example, see International Application WO 92 / 08495, International Application WO 91 / 14438, International Application WO 89 / 12624, US Patent No. 5,314,995 and European Patent Application EP 0396387.
[0197] In some examples, the antibody or antigen-binding fragment thereof is conjugated to a drug. Methods for producing such drug conjugates are known in the art and described herein (see, e.g., Examples 7-9 below). In some examples, the drug is an immunosuppressant (see, e.g., the section below, "Immunosuppressants or Immunomodulatory Drugs," for examples of immunosuppressants. In some examples, the drug is taxol. In some examples, the drug is directly conjugated to the antibody or antigen-binding fragment thereof. In some examples, the drug is conjugated to the antibody or antigen-binding fragment thereof via a linker. Examples of linkers that can be used to conjugate a drug to the antibody or antigen-binding fragment thereof described herein include succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) or maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl (mc- In some examples, the drug is covalently conjugated to the antibody or its antigen-binding fragment. The covalent conjugation of the drug to the antibody or its antigen-binding fragment can be carried out as described in the Examples section below. For example, the drug is chemically modified, for example, using glutaraldehyde to generate a carboxylic acid group, which is then activated using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) / N-hydroxysulfosuccinimide (NHS) chemistry, and the resulting drug reacts preferentially (i.e., conjugates) with the primary amines (e.g., those on lysine) on the antibody or its antigen-binding fragment.
[0198] The antibodies or antigen-binding fragments, variants or derivatives described herein may be composed of amino acids joined together by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. Antibodies may be modified by natural processes, such as post-translational processing, or by chemical modification techniques that are well known in the art. Such modifications are well described in basic textbooks and in more detailed monographs, as well as in a large research literature. Modifications may occur anywhere in the antibody, including the peptide backbone, the amino acid side chains and the amino or carboxyl termini, or on moieties such as carbohydrates. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given antibody. Also, a given antibody may contain multiple types of modifications. Antibodies may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched and branched cyclic antibodies may result from post-translational natural processes or may be made by synthetic methods.Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination; see, e.g., Proteins - Structure And Molecular Properties, TE Creighton, WH Freeman and Company, New York 2nd Ed., (1993); Posttranslational Covalent Modification Of Proteins, B.C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth. Enzymol. 182 (1990), 626-646; Rattan et al., Ann. NY Acad. Sci. 663 (1992), 48-62).
[0199] Also provided herein is a fusion protein comprising an antibody or its antigen-binding fragment, variant or derivative and a heterologous polypeptide.In some embodiments, the fusion protein comprises, consists essentially of, or consists of a polypeptide having any one or more amino acid sequences of the VH region of the antibody described herein or any one or more amino acid sequences of the VL region of the antibody described herein or fragments or variants thereof, and a heterologous polypeptide sequence.In another embodiment, the fusion protein for use in the diagnostic and treatment methods disclosed herein comprises, consists essentially of, or consists of a polypeptide having any one, two, three or fragments, variants or derivatives of the VH-CDRs of the antibody or any one, two, three or fragments, variants or derivatives of the VL-CDRs of the antibody, and a heterologous polypeptide sequence.In some embodiments, the fusion protein comprises a polypeptide having the amino acid sequence of the VH-CDR3 of the antibody described herein or fragments, derivatives or variants thereof, and a heterologous polypeptide sequence, and the fusion protein specifically binds to PNAd. In another embodiment, the fusion protein comprises a polypeptide having the amino acid sequence of at least one VH region of an antibody described herein and the amino acid sequence of at least one VL region of an antibody described herein, or a fragment, derivative or variant thereof, and a heterologous polypeptide sequence. In some embodiments, the VH and VL regions of the fusion protein correspond to a single source antibody (or scFv or Fab fragment) that specifically binds to a PNAd. In yet another embodiment, the fusion protein for use in the diagnostic and treatment methods disclosed herein comprises a polypeptide having any one, two, three or more amino acid sequences of the VH CDRs of an antibody and any one, two, three or more amino acid sequences of the VL CDRs of an antibody, or a fragment or variant thereof, and a heterologous polypeptide sequence.In some embodiments, two, three, four, five, six or more of the VH-CDR(s) or VL-CDR(s) correspond to a single source antibody (or scFv or Fab fragment) described herein. Nucleic acid molecules encoding these fusion proteins are also provided herein.
[0200] Exemplary fusion proteins reported in the literature include T-cell receptors (Gascoigne et al., Proc. Natl. Acad. Sci. USA 84 (1987), 2936-2940; CD4 (Capon et al., Nature 337 (1989), 525-531; Traunecker et al., Nature 339 (1989), 68-70; Zettmeissl et al., DNA Cell Biol. USA 9 (1990), 347-353; and Byrn et al., Nature 344 (1990), 667-670); L-selectin (a homing receptor) (Watson et al., J. Cell. Biol. 110 (1990), 2221-2229; and Watson et al., Nature 349 (1991), 236-2370); 164-167); CD44 (Aruffo et al., Cell 61 (1990), 1303-1313); CD28 and B7 (Linsley et al., J. Exp. Med. 173 (1991), 721-730); CTLA-4 (Lisley et al., J. Exp. Med. 174 (1991), 561-569); CD22 (Stamenkovic et al., Cell 66 (1991), 1133-1144); TNF receptor (Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88 (1991), 10535-10539; Lesslauer et al., Eur. J. Immunol. 27 (1991), 2883-2886; and Peppel et al. al., J. Exp. Med. 174 (1991), 1483-1489 (1991); and the IgE receptor (Ridgway and Gorman, J. Cell. Biol. 115 (1991), Abstract No. 1448).
[0201] As discussed elsewhere herein, the antibody described herein or its antigen-binding fragment, variant or derivative can be fused to heterologous polypeptide to increase the in vivo half-life of polypeptide or to use in immunoassay by using methods known in the art.For example, in some embodiments, PEG can be conjugated to the antibody described herein to increase its in vivo half-life; see, for example, Leong et al., Cytokine 16 (2001), 106-119; Adv. in Drug Deliv. Rev. 54 (2002), 531; or Weir et al., Biochem. Soc. Transactions 30 (2002), 512.
[0202] Furthermore, the antibody or antigen-binding fragment, variant or derivative described herein can be fused to a marker sequence, e.g., a peptide, to facilitate purification or detection. In certain embodiments, the marker amino acid sequence is a hexahistidine peptide (HIS), e.g., a tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311), among others, many of which are commercially available. For example, hexahistidine provides convenient purification of the fusion protein, as described in Gentz et al., Proc. Natl. Acad. Sci. USA 86 (1989), 821-824. Other peptide tags useful for purification include, but are not limited to, the "HA" tag (Wilson et al., Cell 37 (1984), 767), which corresponds to an epitope derived from the influenza hemagglutinin protein, and the "flag" tag.
[0203] Fusion proteins can be prepared using methods well known in the art; see, for example, U.S. Patent Nos. 5,116,964 and 5,225,538. The exact site at which fusion is performed can be empirically selected to optimize the secretion or binding characteristics of the fusion protein. The DNA encoding the fusion protein is then transfected into a host cell for expression.
[0204] The antibody described herein may be used in unconjugated form or may be conjugated to at least one of various molecules, for example, to improve the therapeutic properties of the molecule, to facilitate target detection, or for patient imaging or therapy.The antibody described herein or its antigen-binding fragment, variant or derivative may be labeled or conjugated either before or after purification, if purification is performed.In particular, the antibody described herein or its antigen-binding fragment, variant or derivative may be conjugated to therapeutic drug, prodrug, peptide, protein, enzyme, virus, lipid, biological response modifier, pharmaceutical drug or PEG.
[0205] Conjugates that are immunotoxins containing conventional antibodies have been widely described in the art. Toxins can be coupled to antibodies by conventional coupling techniques, or immunotoxins containing protein toxin moieties can be produced as fusion proteins. The antibodies described herein can be used in a corresponding manner to contain such immunotoxins. Examples of such immunotoxins include those described by Byers, Seminars Cell. Biol. 2 (1991), 59-70 and by Fanger, Immunol. Today 12 (1991), 51-54.
[0206] Those skilled in the art will understand that conjugates can also be assembled using various techniques depending on the selected agent to be conjugated.For example, conjugates with biotin can be prepared, for example, by reacting a PNAd-binding polypeptide with an activated ester of biotin, such as biotin N-hydroxysuccinimide ester.Similarly, conjugates with fluorescent markers can be prepared in the presence of coupling agents, such as those listed herein, or by reaction with isothiocyanates or fluorescein-isothiocyanates.Conjugates of antibodies or their antigen-binding fragments, variants or derivatives described herein can be prepared in a similar manner.
[0207] Also provided herein is an antibody or antigen-binding fragment, variant or derivative thereof described herein conjugated to a diagnostic or therapeutic agent.Antibodies can be used diagnostically, for example, to demonstrate the presence of PNAd-associated disease, to indicate the risk of developing PNAd-associated disease, to monitor the development or progression of PNAd-associated disease, i.e., as part of a clinical testing procedure to determine the effectiveness of a given treatment and / or prophylactic regimen.Detection can be facilitated by coupling the antibody or antigen-binding fragment, variant or derivative thereof to a detectable substance.Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, various positron-emitting metals using positron emission tomography, and non-radioactive paramagnetic metal ions; for example, see U.S. Pat. No. 4,741,900 for metal ions that can be conjugated to antibodies for use as diagnostic methods. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin / biotin and avidin / biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin and aequorin; and examples of suitable radioactive materials include 125I, 131I, 111In or 99Tc.
[0208] An antibody or antigen-binding fragment, variant, or derivative thereof can also be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds include luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt, and oxalate ester.
[0209] One way an antibody or antigen-binding fragment, variant or derivative thereof can be detectably labeled is by linking it to an enzyme and using the linked product in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)" Microbiological Associates Quarterly Publication, Walkersville, Md., Diagnostic Horizons 2 (1978), 1-7); Voller et al., J. Clin. Pathol. 31 (1978), 507-520; Butler, Meth. Enzymol. 73 (1981), 482-523; Maggio, E. (ed.), Enzyme Immunoassay, CRC Press, Boca Raton, Fla., (1980); Ishikawa, E. et al., (eds.), Enzyme Immunoassay, Kgaku Shoin, Tokyo (1981). The enzyme bound to the antibody reacts with a suitable substrate, preferably a chromogenic substrate, in such a way as to produce a chemical moiety that can be detected, for example, by spectrophotometric, fluorometric, or visual means.Enzymes that can be used to detectably label antibodies include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triosephosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholinesterase.Therefore, detection can be achieved by colorimetric methods using a chromogenic substrate for the enzyme.Detection can also be achieved by visual comparison of the extent of enzymatic reaction of the substrate compared to a similarly prepared standard.
[0210] Detection may also be achieved by using any of a variety of other immunoassays.For example, by radioactively labeling antibody or its antigen-binding fragment, variant or derivative, it is possible to detect the antibody by using radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, (March, 1986), which is incorporated herein by reference).Radioisotopes can be detected by means including, but not limited to, gamma counters, scintillation counters or autoradiography.
[0211] Antibodies or antigen-binding fragments, variants, or derivatives thereof can also be detectably labeled using fluorescent metals, such as 152Eu or others of the lanthanide series. These metals can be attached to the antibody using metal chelating groups such as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).
[0212] Techniques for conjugating various moieties to antibodies or antigen-binding fragments, variants, or derivatives thereof are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy" in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985); Hellstrom et al., "Antibodies For Drug Delivery" in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), Marcel Dekker, Inc., pp. 623-53 (1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A" in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), pp. 475-506 (1985). Review”; “Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy” in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press pp. 303-16 (1985); and Thorpe et al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. 62 (1982), 119-158.
[0213] As described, in some embodiments, a moiety that enhances the stability or effectiveness of a binding molecule, such as a binding polypeptide, such as an antibody or its immunospecific fragment, can be conjugated.For example, in some embodiments, PEG can be conjugated to a binding molecule described herein to increase its half-life in vivo.Leong et al., Cytokine 16 (2001), 106; Adv. in Drug Deliv. Rev. 54 (2002), 531; or Weir et al., Biochem. Soc. Transactions 30 (2002), 512A.
[0214] A. Drug-containing polymer particles Also provided herein is a nanoparticle or microparticle conjugated with the antibody or its antigen-binding fragment described herein.The nanoparticle or microparticle described herein can be made of a material that (i) is biocompatible, i.e., when used in a pharmacologic amount, does not cause significant adverse reactions in living animals; (ii) has a functional group that can covalently bind lymphocyte homing adhesion molecules or the antibody or its antigen-binding fragment described herein; (iii) shows low non-specific binding to other molecules; and (iv) is stable in solution, i.e., the particle does not precipitate.The particle can be monodisperse (a single material per particle, e.g., a metal crystal) or polydisperse (multiple crystals per particle, e.g., 2, 3 or 4).
[0215] Several biocompatible particles, such as organic or inorganic nanoparticles or microparticles, are known in the art. Liposomes, dendrimers, carbon materials, and polymeric micelles are examples of organic particles. Quantum dots can also be used. Inorganic particles include metal particles, such as Au, Ni, Pt, and TiO2 nanoparticles or microparticles. Magnetic particles, such as Fe surrounded by dextran or PEG molecules. 2+ and / or Fe 3+Spherical nanocrystals with a core of 10-20 nm can also be used. Colloidal gold nanoparticles are described, for example, in Qian et. al., Nat. Biotechnol. 26(1):83-90 (2008); U.S. Patent No. 7,060,121; U.S. Patent No. 7,232,474; and U.S. Pregrant Patent Application Publication No. 2008 / 0166706. Suitable nanoparticles and methods for constructing and using multifunctional nanoparticles are discussed, for example, in Sanvicens and Marco, Trends Biotech., 26(8): 425-433 (2008).
[0216] In some examples, the particle is a polymer particle.Several biocompatible polymers suitable for use in producing the polymer particles described herein are known in the art, such as polylactic-co-glycolic acid (PLGA), polylactide and polyglycolide.In a specific embodiment, the polymer particle comprises a PLGA polymer.In a specific embodiment, the polymer particle comprises a polylactide polymer.In a specific embodiment, the polymer particle comprises a polyglycolide polymer.
[0217] In some embodiments, to reduce blood protein binding and / or liver and spleen uptake, the polymeric particles can be poly(ethylene glycol)-modified (PEGylated), for example, as described in U.S. Pat. Nos. 7,291,598, 5,145,684, 6,270,806, 7,348,030 and others. For example, in some embodiments, the polymeric particles comprise PEGylated PLGA polymers. In another example, the polymeric particles comprise PEGylated polylactide polymers. In yet another example, the polymeric particles comprise PEGylated polyglycolide polymers. PEGylation creates a stealth-like structure that evades immune recognition by macrophage cells, thus achieving reduced opsonization and enhanced retention of the particles in circulation. Such simple surface modification, for example, PEGylation, can increase the circulation half-life of the particles from minutes to hours or tens of hours.
[0218] In some embodiments, the polymeric particle is bound (linked, e.g., covalently conjugated) to the antibody or antigen-binding fragment thereof described herein. The antibody or antigen-binding fragment thereof can be bound to the polymeric particle via the functional group of the polymer of the polymeric nanoparticle. For example, the antibody or antigen-binding fragment thereof can be conjugated to the polymeric particle.
[0219] The nanoparticles or microparticles are bound (linked) to the antibodies or antigen-binding fragments thereof described herein via functional group(s). In some embodiments, the nanoparticles or microparticles are associated with a polymer that contains functional group(s) and helps to keep the metal oxides dispersed with each other. The polymer can be a synthetic polymer, such as, but not limited to, polyethylene glycol or silane, a natural polymer or a derivative of either synthetic or natural polymers or a combination thereof. Useful polymers are hydrophilic. In some embodiments, the polymer "coating" is not a continuous film around the magnetic metal oxide, but a "mesh" or "cloud" of extended polymer chains that are attached to and surround the metal oxide. The polymer can include polysaccharides and derivatives, including dextran, pullanan, carboxydextran, carboxmethyl dextran and / or reduced carboxymethyl dextran. The metal oxide can be an aggregate of one or more crystals that contact each other or are individually captured or surrounded by the polymer.
[0220] In other embodiments, the nanoparticles or microparticles are associated with non-polymeric functional compositions. Methods for synthesizing stabilized, functionalized nanoparticles or microparticles without associated polymers are known and are also within the scope of the present invention. Such methods are described, for example, in Halbreich et al., Biochimie, 80 (5-6):379-90, 1998.
[0221] In some embodiments, the immunosuppressant or immunomodulatory agent described herein may be encapsulated within, e.g., mixed therein, or under a coating of, a nanoparticle or microparticle. In some embodiments, the immunosuppressant or immunomodulatory agent described herein may be conjugated to the nanoparticle or microparticle, e.g., on the exterior of its surface.
[0222] i. Immunosuppressants or immunomodulatory drugs Three classical immunosuppressants, cyclosporine A, rapamycin and tacrolimus, have been successfully incorporated into the drug-containing particles described herein, which showed controlled drug release and suppression of T cell activity in vitro (Azzi, J., et al., FASEB J 24: 3927-3938, 2010; Tang, L., et al., J. Transplantation, 2012: 896141, 2012; Tong, R. & Cheng, JJ, Macromolecules 45: 2225-2232, 2012).
[0223] In some embodiments, tacrolimus (also known as TAC, FK-509 or fujimycin) is incorporated into the drug-containing particles described herein.Tacrolimus is an immunosuppressant drug that is mainly used after allogeneic organ transplantation to reduce host immune response and reduce the risk of organ rejection.At the molecular level, tacrolimus is a macrolide lactone that can reduce interleukin-2 (IL-2) production by T cells (Liu J, Farmer J, Lane W, Friedman J, Weissman I, Schreiber S, Cell 66 (4): 807-815, 1991). Other suitable immunosuppressants or immunomodulatory drugs that can be incorporated into the delivery system include, but are not limited to, mycophenolic acid, mofetil, cyclosporine, sirolimus, fingolimod, myriocin, cyclophosphamide, corticosteroids (e.g., cortisol, corticosterone, cortisone or aldosterone), rapamycin, mycophenolic acid, mofetil, checkpoint inhibitors (e.g., anti-CTLA-4 antibodies, anti-PD1 antibodies, anti-PDL1 antibodies), anti-inflammatory agents (e.g., anti-TNF drugs, e.g., adalimumab, etc.), chemotherapeutic agents and monoclonal antibodies, e.g., anti-CD3 antibodies, anti-CD25 antibodies, anti-IL6 antibodies, CTLA-4-Ig, adalimumab, anti-CD52 antibodies (e.g., alemtuzumab), etc. In some embodiments, taxol is incorporated into the drug-containing particles described herein. In some embodiments, the immunosuppressant or immunomodulatory drug has one or more hydroxyl or thiol groups and can function as a polymerization initiator in the presence of certain catalysts.
[0224] In some embodiments, the drug is a chemotherapy drug.Chemotherapy can be, for example, the use of cytotoxins or cytotoxic drugs that are harmful to cells.Examples include taxol, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, mitoxantrone, mithramycin, actinomycin D and puromycin and their analogs or homologs. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa, chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamineplatinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and mitotic inhibitors (e.g., vincristine and vinblastine). See, e.g., Johnson and Win, Oncoimmunology. 2018 Mar 13;7(4):e1408744; Chowdhury et al., J Intern Med. 2018 Feb;283(2):110-120; Tang et al., Nature Reviews Drug Discovery 17:854-855 (2018).
[0225] ii. Synthesis of drug-containing polymer particles There are a variety of methods by which drug-containing nanoparticles or microparticles can be prepared, but in all methods the result must be a particle that has functional groups that can be used to link the particle to an antibody or antigen-binding fragment thereof as described herein.
[0226] In some embodiments, the immunosuppressant or immunomodulatory drug described herein can be encapsulated, e.g., mixed therein, or under the coating of nanoparticles or microparticles. Such drug-encapsulated particles can be synthesized, for example, using the nanoprecipitation method described in Tang, L., et al., J. Transplantation, 2012: 896141, 2012, the disclosure of which is incorporated herein by reference. Briefly, the drug to be delivered and the PEGylated polymer can be dissolved in a suitable organic solvent. The resulting solution can be added dropwise into a non-solvent, e.g., water, under vigorous stirring to form polymeric particles with PEGylated drug encapsulated. The particle suspension can then be stirred at room temperature to evaporate the organic solvent. An aliquot of the particle suspension can be centrifuged, and the supernatant can be analyzed, for example, by reverse-phase HPLC, to determine the incorporation efficiency and loading of the drug on the particles. The particles can then be purified and collected, for example, by ultrafiltration. Optionally, a cryoprotectant, such as bovine serum albumin (BSA), can be added to the particle solution, which can be lyophilized and stored at −20° C. The size and polydispersity of the resulting particles can be determined by dynamic light scattering (DLS) and / or scanning electron microscopy (SEM).
[0227] In some embodiments, the immunosuppressant or immunomodulatory drug described herein can be conjugated to nanoparticles or microparticles, for example, on the outside of their surface. Such drug-conjugated particles can be synthesized using the method described in Azzi, J., et al., FASEB J 24: 3927-3938, 2010, or in International Publication WO 2008 / 109483, the disclosure of which is incorporated herein by reference. Briefly, the drug to be delivered can be mixed with one or more cyclic monomers and a catalyst in a suitable solvent. The drug acts as an initiator in a ring-opening polymerization reaction, forming a drug-polymer conjugate in which the drug is covalently bound to the polymer. Because the drug is used as the initiator of polymerization, the efficiency of conjugation of the drug to the polymer is extremely high, and the drug loading percentage can be controlled by adjusting the monomer / initiator ratio. The drug-polymer conjugate and PEGylated polymer can then be added dropwise into a non-solvent, e.g., water, under vigorous stirring to form PEGylated drug-conjugated polymeric particles. The particle suspension can then be stirred at room temperature to evaporate the organic solvent. The particles can be purified and collected, e.g., by ultrafiltration. Optionally, a cryoprotectant, e.g., bovine serum albumin (BSA), can be added to the particle solution, which can be lyophilized and stored at -20°C. The size and polydispersity of the resulting particles can be determined by dynamic light scattering (DLS) and / or scanning electron microscopy (SEM).
[0228] Suitable monomers for ring-opening polymerization include various cyclic ring-opening monomers, such as cyclic esters, cyclic carbonates, cyclic siloxanes, cyclic phosphates, cyclic peptides or amino acid derivatives, or cyclic phosphazanes. Exemplary cyclic monomers include lactide or glycolide.
[0229] The polymeric particles described herein can be used to deliver any small molecule drug that contains at least one functional group, such as a hydroxyl group or a thiol group, that can initiate a ring-opening polymerization reaction. The drug may contain multiple such polymerization initiator groups, such as multiple hydroxyl groups or thiol groups. In some embodiments, the drug contains only one such polymerization group. The hydroxyl group may be a primary, secondary or tertiary hydroxyl group. Similarly, the thiol group may be a primary, secondary or tertiary thiol group. The hydroxyl group may also be a phenolic hydroxyl group. In some embodiments, the drug contains one or more non-phenolic hydroxyl groups. In some embodiments, the drug contains one or more non-phenolic hydroxyl groups that are primary or secondary hydroxyl groups. In some embodiments, the drug contains a single non-phenolic hydroxyl group. In some embodiments, the drug contains a single primary or secondary hydroxyl group. In some embodiments, the immunosuppressant or immunomodulatory drug with one or more hydroxyl or thiol groups functions as a polymerization initiator in the presence of certain catalysts.
[0230] Several catalysts can be used to promote the formation of drug-containing polymeric particles. Exemplary catalysts include a number of metal oxides (M-OR) and alcohol-metal oxides (RO-M) that have been developed for the controlled living polymerization of cyclic monomers (O. Dechy-Cabaret, B. Martin-Vaca, & D. Bourissou, Chemical Reviews 104: 6147-6176, 2004). Metal oxides can be prepared in situ by mixing hydroxyl-containing compounds with active metal complexes, such as metal amide compounds (BM Chamberlain, M. Cheng, DR Moore, TM Ovitt, EB Lobkovsky, GW Coates, J. Am. Chem. Soc. 123: 3229, 2001). For example, (BDI)MgN(TMS)2, a highly active catalyst for the polymerization of lactide, can be used (Chamberlain, 2001). Certain Zn catalysts, such as (BDI)ZnN(TMS)2, promote rapid initiation and relatively slow chain propagation and can be used as polymerization catalysts. Zn-mediated lactide polymerization can result in polymers with narrow polydispersity. Other useful catalysts include Ca and Fe catalysts. Because Mg, Zn, Ca and Fe are elements found in the human body, catalysts containing these elements have better safety profiles than other active catalysts containing Al and Sn. Exemplary Zn, Mg, Ca and Fe catalysts include organic catalysts and are described in WO2008 / 109483. In some embodiments, Zn catalysts, such as (BDI)ZnN(TMS)2, are used to initiate drug-containing polymeric particles.
[0231] The particles described herein exhibited high drug loading (about 50%) and loading efficiency (98-100%), well-controlled drug release kinetics without burst release effect, and highly controlled particle size with very narrow size distribution (Tong, R. & Cheng, J., Angew. Chem., Int. Ed. 47: 4830-4834, 2008; Tong, R. & Cheng, J., J. Am. Chem. Soc. 131: 4744-4754, 2009).
[0232] Particle size can be controlled by adjusting reaction conditions, for example, by varying temperature as described in U.S. Patent No. 5,262,176. Uniform particle size material can also be produced by fractionating particles using centrifugation, ultrafiltration or gel filtration, for example, as described in U.S. Patent No. 5,492,814.
[0233] The size of the drug-containing polymer particles described herein may range from about 2 nm to about 500 μm. In some embodiments, the drug-containing polymer particles have an overall size in the range of about 0.01 μm to about 10 μm, such as about 0.05 μm to about 5 μm, about 0.1 μm to about 3 μm, about 1 μm to about 2.5 μm. In some embodiments, the drug-containing polymer particles have an overall size in the range of about 500 nm to about 5 μm. In some embodiments, the drug-containing polymer particles have an overall size in the range of about 1 μm to about 2.5 μm. In some embodiments, the drug-containing polymer particles have an overall size in the range of about 200 nm to about 800 nm. In some embodiments, the drug-containing polymer particles have an overall size in the range of 2 to 20 nm, which is particularly useful for delivery to cells.
[0234] In some embodiments, the drug-containing polymeric particles disclosed herein can be surface-modified to provide functional groups that can be used to link the particles to the antibody or antigen-binding fragments thereof described herein.For example, the particles can be functionalized according to a version of the method of Albrecht et al., Biochimie, 80(5-6): 379-90, 1998. Dimercapto-succinic acid can be coupled to the particles to provide carboxyl functional groups.Functionalized refers to the presence of amino or carboxyl or other reactive groups that can be used to link desired moieties to the particles.
[0235] For example, carboxyl-functionalized nanoparticles or microparticles can be prepared according to the method of Gorman (see WO 00 / 61191). Carboxyl-functionalized particles can also be prepared from polysaccharide-coated particles by reaction with bromo- or chloroacetic acid in a strong base to bind carboxyl groups. Furthermore, carboxyl-functionalized particles can be prepared from amino-functionalized particles by converting the amino to carboxyl groups by using reagents such as succinic anhydride or maleic anhydride.
[0236] The particles can also be treated with periodic acid to form aldehyde groups. The aldehyde-containing particles can then be reacted with a diamine (e.g., ethylenediamine or hexanediamine), which forms a Schiff base, followed by reduction with sodium borohydride or sodium cyanoborohydride.
[0237] Also, dextran coated particles can be made and crosslinked with, for example, epichlorohydrin. The addition of ammonia reacts with the epoxy groups to generate amine groups, see Hogemann et al., Bioconjug. Chem. 2000. 11(6):941-6, and Josephson et al., Bioconjug. Chem., 1999, 10(2):186-91.
[0238] Carboxyl-functionalized particles can be converted to amino-functionalized magnetic particles by the use of water-soluble carbodiimides and diamines, such as ethylenediamine or hexanediamine.
[0239] For use with biotinylated binding moieties, such as oligonucleotides or polypeptides, avidin or streptavidin can be attached to the particles.See, for example, Shen et al., Bioconjug. Chem., 1996, 7(3):311-6.Similarly, for use with avidin-labeled binding moieties, biotin can be attached to the particles.
[0240] In some embodiments, to reduce blood protein binding and / or liver and spleen uptake, drug-containing polymeric particles can be PEGylated, for example, as described in U.S. Patent No. 7291598, U.S. Patent No. 5145684, U.S. Patent No. 6270806, U.S. Patent No. 7348030 and others. PEGylation creates a stealth-like structure that avoids immune recognition by macrophage cells, thus achieving suppression of opsonization and enhanced retention of particles in circulation.Such simple surface modification, for example PEGylation, can increase the circulation half-life of particles from minutes to hours or tens of hours.
[0241] iii. Method of Conjugation The drug-containing polymeric particles described herein are conjugated to an antibody or antigen-binding fragment thereof described herein.
[0242] In some embodiments, the antibody or antigen-binding fragment thereof can be linked to the drug-containing polymeric particle by a covalent bond, e.g., by a chemical bond between a functional group on the molecule and a functional group on the drug-containing polymeric particle. The functional group can be an amino or carboxyl or other reactive group that can be used to attach a desired moiety, e.g., an antibody or antigen-binding fragment thereof, to the particle.
[0243] In some embodiments, the antibody or antigen-binding fragment thereof described herein can be linked to drug-containing polymeric particles via linker or binder.Linker or binder can have terminal amino, carboxy, sulfhydryl or phosphate group.Illustrative examples of useful linker or binder include organic polymers, such as polyethylene glycol (PEG) and its derivatives, proteins and small molecules.
[0244] VI.How to use As mentioned above, the present disclosure is based at least in part on the development of anti-PNAd antibodies with improved binding affinity to cells expressing PNAd (Example 6) and improved ability to block T cell homing to lymph nodes (Example 4). Administration of drugs conjugated to the anti-PNAd antibodies described herein resulted in reduced tumor growth, reduced tumor metastasis, and reduced tumor-draining lymph node fibrosis (Example 7), in addition to increased survival time (Example 8). Furthermore, administration of drugs conjugated to the anti-PNAd antibodies described herein also increased survival time after heart transplantation (Example 9). Thus, the antibody-drug conjugates described herein and in the following examples can be used to treat primary tumors and local metastases in lymph nodes and distant metastases; this use of the antibodies was not predicted, since metastatic lesions were not known to express HEV. Thus, the present disclosure provides compositions and methods for suppressing lymphocyte-mediated immune response in a subject in need thereof, treating or delaying the progression of autoimmune diabetes in a subject in need thereof, treating lymphocyte-mediated inflammation in a subject in need thereof, and treating or reducing metastasis of peripheral lymph node addressin (PNAd)-expressing malignancies in a subject in need thereof. These methods may include identifying a subject in need of treatment and administering one or more of the compositions described herein to the subject. A subject in need of treatment may be identified, for example, by a physician. In some embodiments, the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof) may be used in a method of suppressing lymphocyte-mediated immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof).In some embodiments, the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof) may be used in a method of treating or delaying the progression of autoimmune diabetes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof). In some embodiments, the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof) may be used in a method of treating lymphocyte-mediated inflammation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof). In some embodiments, the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof) may be used in a method of treating or reducing metastasis of a PNAd-expressing malignancy in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof described herein (or a composition or particle (e.g., drug-containing particle) comprising the antibody or antigen-binding fragment thereof). In some embodiments, the PNAd-expressing malignancy is lymphoma. In some embodiments, the PNAd-expressing malignancy is cancer. In some examples, the cancer is breast cancer. In some examples, the cancer is a primary tumor. In some examples, the cancer is a regional metastasis. In some examples, the cancer is a regional metastasis in lymph nodes. In some examples, the cancer is a distant metastasis (i.e., distal to the location of the primary tumor).
[0245] As described above, the antibodies and antigen-binding fragments thereof described herein are particularly useful in developing drug-containing polymeric particles that can mimic lymphocyte migration in vivo and specifically deliver drugs, such as immunosuppressants or immunomodulatory drugs, to lymphoid tissues and sites of chronic inflammation where T cell activation and T cell-mediated injury occur. Thus, the present disclosure provides compositions and methods for treating or delaying disease progression in subjects (e.g., humans) who require immunosuppression for, for example, autoimmune or inflammatory disorders, such as type 1 diabetes or rheumatoid arthritis, and post-transplant immunosuppression in, for example, heart or other organ transplants. The present disclosure also provides compositions and methods for treating or delaying disease progression in subjects (e.g., humans) with cancer (e.g., lymphoma or breast cancer). The present disclosure also provides methods for treating or delaying the progression of malignant tumors, such as cancers, such as lymphomas, where lymphocyte homing processes play a role in tumor dissemination and / or where the malignant tumor expresses PNAd, by delivering chemotherapeutic drugs to lymphoid tissues.
[0246] These methods may include identifying a subject in need of treatment and administering to the subject one or more of the compositions described herein. A subject in need of treatment may be identified, for example, by a physician.
[0247] A. Methods of Treating Autoimmune Diabetes Type 1 diabetes (T1D) is characterized by the autoimmune destruction of insulin-producing β-cells of pancreatic islets by autoreactive T cells (Hoglund, P., et al., J Exp Med 189: 331-339, 1999). Central to the pathogenesis of autoimmune diabetes is the presentation of islet antigens by antigen-presenting cells from the draining pancreatic lymph nodes to T cells, leading to the activation of autoreactive T cells (Roncarolo, MG & Battaglia, M., Nat Rev Immunol 7: 585-598, 2007). Several studies have shown that pancreatic lymph nodes play an important role in the pathogenesis of autoimmune diabetes (Katz, JD, Wang, B., Haskins, K., Benoist, C. & Mathis, D. Cell 74: 1089-1100, 1993;Hoglund, P., et al., J Exp Med 189, 331-339, 1999;Turley, S., Poirot, L., Hattori, M., Benoist, C. & Mathis, D., J Exp Med 198: 1527-1537, 2003;Turley, SJ, Lee, JW, Dutton-Swain, N., Mathis, D. & Benoist, C., Proc Natl Acad Sci USA 102: 17729-17733, 2005). Following priming, activated autoreactive T cells are recruited to the pancreas and cause insulitis.
[0248] The PNAd pathway has been shown to regulate lymphocyte trafficking to lymphoid tissues in NOD mice (Hanninen, A., Salmi, M., Simell, O., Andrew, D. & Jalkanen, S., Blood 88: 934-944, 1996; Xu, B., et al., J Exp Med 197: 1255-1267, 2003;Xu, B., Cook, RE & Michie, SA, J Autoimmun. 35: 124-129, 2010). Furthermore, PNAd is upregulated in venous endothelium in inflammatory conditions and autoimmune diseases, such as T1D (Michie, SA, Streeter, PR, Bolt, PA, Butcher, EC & Picker, LJ, Am J Pathol 143: 1688-1698, 1993;Mikulowska-Mennis, A., Xu, B., Berberian, JM & Michie, SA, Am J Pathol 159: 671-681, 2001;Penaranda, C. & Bluestone, JA, Immunity 31: 534-536, 2009). Inflammatory signals and endothelial cell activation during insulitis have been reported to confer islet endothelial morphology and characteristics to PNAd-expressing HEVs.Thus, the development of insulitis has been reported to be associated with islet expression of PNAd (Hanninen, A., Salmi, M., Simell, O., Andrew, D. & Jalkanen, S., Blood 88, 934-944, 1996;Faveeuw, C., Gagnerault, MC, Kraal, G. & Lepault, F., Int Immunol 7: 1905-1913, 1995;Yang, XD, et al., Proc Natl Acad Sci USA 91: 12604-12608, 1994;Yang, XD, et al., J Autoimmun 7: 859-864, 1994;Faveeuw, C., Gagnerault, MC & Lepault, F., J Immunol 152: 5969-5978, 1994;Hanninen, A., Salmi, M., Simell, O. & Jalkanen, S., Diabetes 45: 1173-1180, 1996;Dong, H., Burke, SD & Croy, BA, Placenta 29: 201-209, 2008). The interaction of leukocytes with endothelial cells via adhesion molecules offers great opportunities to design different strategies, such as the development of inhibitors or antibodies targeting leukocyte trafficking (Mackay, CR, Nat Immunol 9: 988-998, 2008).
[0249] The antibody or its antigen-binding fragment or its conjugate described herein can be used to selectively deliver immunosuppressant to pancreatic lymph nodes and pancreas to effectively suppress autoreactive T cells and treat or delay the progression of autoimmune diabetes, such as type 1 diabetes (T1D).Subjects with some pancreatic β-cell function are more likely to benefit from this treatment method.Such subjects can be identified, for example, by determining that the C-peptide level of the subject is above a threshold value.
[0250] B. Post-transplant immunosuppression After tissue or organ transplantation, immune cells are activated against exogenous antigens present on the allograft. Activated immune cells can migrate to the transplanted tissue or organ and cause damage there. Direct delivery of small amounts of immunosuppressant drugs to the site where immune cells are activated can reduce their activation and increase the survival rate of allograft organs. Such targeted delivery of immunosuppressant drugs also reduces the toxicity seen in systemic administration of large amounts of immunosuppressant medicines. The compositions described herein are useful vehicles for delivering immunosuppressant drugs directly to the site of organ transplantation and increasing the survival rate of allograft organs.
[0251] C. Methods of Treating Lymphoma The compositions described herein can also be used to treat lymphoma, such as PNAd-expressing lymphoma.It has been found that lymphocyte homing process plays a role in the dissemination of some tumors.For example, the dissemination of non-Hodgkin's lymphoma (NHL) is mediated by lymphocyte homing program (Pals ST, de Gorter DJJ, and Spaargaren M, Blood 110(9): 3102-3111, 2007). Other exemplary lymphomas that can be treated by the compositions disclosed herein include small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Burkitt's lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), cutaneous lymphomas, e.g., cutaneous T-cell lymphoma (CTCL), intestinal lymphomas, e.g., intestinal T-cell lymphoma (ITL), nodal T-cell lymphoma, extranodal lymphoma arising in the gut-associated lymphoid tissue or skin, adult T-cell leukemia / lymphoma (ATLL) and B-cell lymphoma of mucosa-associated lymphoid tissue (MALT), primary follicular lymphoma (FL), B-cell chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia (HCL).
[0252] In some embodiments, the antibodies or antigen-binding fragment conjugates thereof described herein can be used to treat or delay the progression of PNAd-expressing lymphoma.
[0253] VII. Pharmaceutical Compositions A therapeutically effective amount of one or more of the antibodies or antigen-binding fragments or conjugates described herein can be incorporated into pharmaceutical compositions suitable for administration to subjects, for example, humans. Such compositions usually include antibodies or antigen-binding fragments or conjugates thereof and pharmaceutically acceptable carriers. In this specification, the term "pharmaceutically acceptable carriers" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc., that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known. Except where any conventional media or agent is incompatible with the active compound, such media can be used in the compositions described herein. Supplementary active compounds, for example inhibitors of the degradation of ligands, can also be incorporated into the composition.
[0254] Pharmaceutical compositions can be formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, intradermal or subcutaneous application can contain the following components: sterile diluents, such as water for injection, saline solution, hardened oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetate, citrate or phosphate, and agents for adjusting tonicity, such as sodium chloride or dextrose. pH can be adjusted using acids or bases, such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[0255] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, CREMOPHOR EL™ (polyethoxylated castor oil; BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be protected against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferable to include isotonic agents in the composition, such as sugars, polyalcohols, such as mannitol, sorbitol, sodium chloride. Prolonged absorption of the injectable composition can be brought about by including in the composition an agent that delays absorption, such as aluminum monostearate and gelatin.
[0256] Sterile injectable solution can be prepared by incorporating the composition (e.g., the agent described herein) in the required amount into a suitable solvent with one or a combination of the above-listed components, and then optionally sterilizing by filtration.Generally, dispersion is prepared by incorporating active compound into a sterile vehicle that contains a basic dispersion medium and other components required from the above-listed ones.For the preparation of sterile injectable solution, the preferred preparation method for sterile powder is vacuum drying and freeze-drying, which obtains a powder of active ingredient and any additional desired ingredients from the solution that has been previously sterilized and filtered.
[0257] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with an excipient and used in the form of tablets, troches or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, where the compound in the fluid carrier is applied orally, swished, expectorated or swallowed. Pharmaceutically compatible binding agents and / or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like may contain the following ingredients, or compounds of a similar nature: a binder, such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient, such as starch or lactose, a disintegrating agent, such as alginic acid, PRIMOGEL™ (sodium carboxymethyl starch) or corn starch; a lubricant, such as magnesium stearate or STEROTES™; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; or a flavoring agent, such as peppermint, methyl salicylate, or orange flavoring.
[0258] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, a penetrant suitable for the barrier to be permeated is used in the formulation. Such penetrants are generally known, and include, for example, for transmucosal administration, detergents, bile salts and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into ointments, salves, gels or creams as generally known in the art.
[0259] In some embodiments, the active compound (e.g., an antibody or its antigen-binding fragment or its conjugate) is prepared with a carrier that protects the compound from rapid elimination from the body, for example, a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid can be used. Methods for preparing such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
[0260] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration. In one aspect, the pharmaceutical composition can be included as part of a kit.
[0261] In general, the dosage used for administering pharmaceutical compositions facilitates the intended purpose for prevention and / or treatment without undesirable side effects, such as toxicity, irritation or allergic reaction.Although individual needs may vary, determining the optimal range of effective amount of formulation is within the skill of the art.Human dosage can be easily extrapolated from animal studies (Katocs et al., Chapter 27 In: "Remington's Pharmaceutical Sciences", 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990). In general, the dosage required to provide an effective amount of the formulation, which can be adjusted by one of skill in the art, will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, nature of concurrent therapy, and, if necessary, the nature and extent of the desired effect(s) (Nies et al., Chapter 3, In: Goodman & Gilman's "The Pharmacological Basis of Therapeutics", 9th Ed., Hardman et al., eds., McGraw-Hill, New York, NY, 1996).
[0262] VIII. Administration A therapeutically effective amount of one or more of the compositions described herein may be administered by standard methods, e.g., by one or more routes of administration, e.g., by one or more routes of administration currently approved by the U.S. Food and Drug Administration (FDA; see, e.g., world wide web address fda.gov / cder / dsm / DRG / drg00301.htm), e.g., orally, topically, mucosally or parenterally, e.g., intravenously or intramuscularly.
[0263] IX. Kit The present invention also includes kits for use in the methods described herein.In some embodiments, the kits include one or more doses of the compositions described herein.The composition, shape and type of dosage form for induction and maintenance regimen can vary according to the requirements of the subject.For example, dosage form can be parenteral dosage form, oral dosage form, delayed or controlled release dosage form, topical and mucosal dosage form, including any combination thereof.
[0264] In certain embodiments, the kit contains in a package or container one or more of the following: (1) one or more doses of the compositions described herein, (2) one or more pharma- ceutically acceptable adjuvants or excipients (e.g., pharma- ceutically acceptable salts, solvates, hydrates, stereoisomers, or clathrates), (3) one or more vehicles for administration of the doses, (5) instructions for administration. Embodiments in which two or more, including all, of components (1)-(5) are found in the same container may also be used.
[0265] In the case where a kit is provided, the different components of the included composition may be packaged in separate containers and mixed immediately before use. Packaging the components separately in this way allows for long-term storage without loss of the function of the active components. In the case where more than one bioactive agent (e.g., an antibody or its antigen-binding fragment or its conjugate) is included in a particular kit, the bioactive agents may be (1) packaged separately and mixed separately with a suitable (different but similarly compatible) adjuvant or excipient immediately before use, (2) packaged together and mixed together immediately before use, or (3) packaged separately and mixed together immediately before use. In the case where the selected compounds (e.g., an antibody or its antigen-binding fragment or its conjugate) remain stable after mixing, the compounds may be mixed at a time other than immediately before use, including, for example, minutes, hours, days, months, years, and at the time of manufacture.
[0266] The compositions contained in the specific kits of the present invention can be provided in any type of container so that the life span of the different components is optimally preserved and is not absorbed or altered by the material of the container.Materials suitable for these containers can include, for example, glass, organic polymers (e.g., polycarbonate and polystyrene), ceramics, metals (e.g., aluminum), alloys, or any other material that is commonly used to hold similar reagents.Exemplary containers can include, but are not limited to, test tubes, vials, flasks, bottles, syringes, etc.
[0267] As noted above, the kits may also be supplied with instructional materials. These instructions may be printed and / or provided on electronically readable media, including but not limited to floppy disks, CD-ROMs, DVDs, Zip disks, video cassettes, audio tapes, and flash memory devices. Alternatively, the instructions may be published on an Internet website or distributed to users via e-mail. EXAMPLES
[0268] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims. [Example 1] MHA112 monoclonal antibody (mAb) recognizes HEV in mice and humans Two GlcNAc6ST1 / 2 / 4 triple knockout (KO) mice lacking peripheral lymph node vascular addressin (PNAd) were cultured using sialyl Lewis acidase (SSA)-dependent endothelial cell line (ESL) and endothelial cell line (ESL). XThe mice were immunized with a Chinese hamster ovary (CHO) cell line expressing CD34 decorated with (sLeX)-type glycans. MHA112 single hybridoma clones were identified by HEV immunofluorescence staining. Supernatants of MHA112 hybridoma cultures were collected and used to stain mouse lymph node (LN) and human tonsil sections. Figure 1A shows a low-magnification image of high endothelial venule (HEV) structures in mouse LNs, which were recognized by MHA112 hybridoma supernatants. High-magnification images (Figure 1B) demonstrated that MHA112 stained mouse and human HEV structures. [Example 2] MHA112 mAb isotyping Then, an isotyping enzyme-linked immunosorbent assay (ELISA) was performed to identify the immunoglobulin (Ig) form of MHA112 mAb. As shown in Figure 2A, MHA112 supernatant was positive in anti-IgM coated wells. These data indicated that the MHA112 isotype was mouse IgM. [Example 3]
[0269] Transport of MHA112 mAb-conjugated NPs into LNs MECA79 is a monoclonal antibody that recognizes all known L-selectin ligands on endothelial venules, including a subset of CD34, GlyCAM-1, and MAdCAM-1 (Hemmerich, S., Butcher, EC & Rosen, SD, J Exp Med 180, 2219-2226, 1994). MECA79 was generated by using collagenase-dispersed mesenteric and peripheral lymph node stromal elements as immunogens and was selected based on selective staining of peripheral lymph node HEVs (Streeter et al., J. Cell. Biol. 107:1853-1862, 1988).
[0270] Mice were intravenously injected with MHA112-conjugated, MECA79-conjugated and unconjugated particles (loaded with IR800 dye). Analysis 24 hours after injection showed high signals in the LNs of MHA112-NP and positive control MECA79-NP groups compared to mice injected with unconjugated IR800-NP (Figure 3A). Sections of axillary LNs were then stained to evaluate the intra-LN distribution of NPs at 24 hours after injection. DAPI (4',6-diamidino-2-phylindole) was used to stain cell nuclei blue. MECA79 mAb was used to stain PNAd green and visualize NPs in red. At 24 hours MECA79-NPs and MHA112-NPs were localized around the HEV. Significantly less NPs were detected in the LNs of mice injected with untargeted NPs (Figure 3B). Transport of MHA112-NP to LNs was comparable to MECA79-NPs, highlighting the specificity of MHA112 mAb in efficiently transporting NPs to LNs. [Example 4]
[0271] MHA112 mAb blocked T cell homing to LNs To test whether MHA112 mAb can block T cell homing to LNs in vivo, T cells were labeled with fluorescein isothiocyanate (FITC) fluorescent dye, transferred into naive mice, and their distribution was assessed 19 hours later. MHA112 (anti-HEV) reduced the number of transferred T cells that entered the axillary (Axi), inguinal (Ing), and brachial (Bra) LNs by more than 25% (Figure 4). Furthermore, the number of T cells that entered the mesenteric LNs in the presence of MHA112 was also reduced by approximately 12% of the PBS control (Figure 4). In contrast, MECA79 did not reduce the number of transferred T cells that entered the axillary, inguinal, brachial, or mesenteric LNs (Figure 4). Labeled T cells that entered the spleen were unchanged in the three groups (Figure 4). These data indicated that MHA112 mAb may share binding sites with T cells in HEV and blocked T cell homing in vivo. MHA112 mAb was significantly better at blocking T cell homing than MECA79 antibody. [Example 5]
[0272] MHA112 mAb sequence The sequences of the MHA112 heavy and light chain variable regions (VH and VL, respectively) are shown in FIG. 5, with the framework regions (FR1-FR4) and IMGT complementarity determining regions (CDR1-CDR3) depicted.
[0273] Materials and methods used in Examples 1 to 5 Immunization and antibody isolation Two GlcNAc6ST1 / 2 / 4 triple KO mice lacking PNAd were immunized with a CHO cell line expressing CD34 decorated with sLeX-type glycans. After the third immunization, the mice were sacrificed for hybridomas. Approximately 500 single clones were screened by HEV staining. A monoclonal antibody, MHA112, against mouse and human HEV was identified.
[0274] immunohistochemistry Fresh LNs were embedded in tissue freezing medium. Cryostat sections (8 μm thick) were prepared for imaging by fluorescence confocal microscopy. MHA112 was used as the primary antibody for tissue staining. Anti-mouse IgM conjugated with Alexa Fluor 488 was used as the secondary antibody. DAPI was used to stain cell nuclei.
[0275] ELISA 96-well ELISA plates were coated with goat anti-mouse IgM, IgG1, IgG2a, IgG2b, IgG3 (5 μg / mL) and incubated overnight at 4° C. The wells were then blocked with 5% BSA in Dulbecco's phosphate-buffered saline (DPBS) and washed three times with DPBS+0.05% Tween-20 (PBST). MHA112 hybridoma supernatant (1:500) was then added to the wells for a 1-h incubation period at 37° C. The wells were washed again with PBST and incubated with goat anti-mouse immunoglobulin (Ig) conjugated with horseradish peroxidase (HRP) (Invitrogen) for 1 h at 37° C. After washing three times with PBST, samples were then treated with 3,3',5,5'-tetramethylbenzidine and absorbance was recorded at 450 nm using a VersaMax microplate reader (Molecular Devices Corp.).
[0276] Lymph node transport MECA79 and MHA112 mAbs were conjugated to the functionalized surface of nanoparticles (NPs) using thiol-maleimide chemistry. MECA79 and MHA112 mAbs were pretreated with a mild reducing agent (tris(2-carboxythyl)phosphine (TCEP), 15 min at room temperature) to cleave the thiol groups and immediately mixed with the NP suspension. The maleimide groups on the NPs were covalently conjugated to the cleaved thiols of MECA79 and MHA112 antibodies. MECA79-NPs and MHA112-NPs were stored at 4 °C before use. For biodistribution studies, 8-10 week-old C57BL / 6J (JAX number 000664) mice were used. Samples were administered intravenously by retro-orbital injection. A UVP iBOX Explorer imaging microscope (UVP) equipped with a 750-780 nm excitation filter and an 800 nm long-pass emission filter was used to study the transport of fluorescent MECA79-IR-NPs and MHA112-IR-NPs. Several LNs, including axillary, brachial, inguinal, renal and mesenteric, were collected and imaged using the iBOX.
[0277] T cell blockade Spleens were harvested from three C57BL / 6 mice. Single cell suspensions were prepared and cells were positively enriched for T cells using MACS reagents and columns (Miltenyi Biotech, Bergisch Gladbach, Germany) according to the manufacturer's instructions. For injection, T cells were labeled with CellTracker Green (Thermo Fisher), resuspended in sterile saline, and 5 million T cells were injected into each mouse in 100 μl. Blocking antibodies MHA112 and MECA79 were administered intraperitoneally (ip) at 200 μg in 200 μl per mouse 2 hours prior to T cell injection. 19 hours after transplantation, mice were euthanized and LNs were processed for flow cytometry. [Example 6]
[0278] MHA112 binding affinity To compare the affinity of MHA112 with MECA79, a cell-based ELISA was performed. CHO cells expressing PNAd (CHO-PNAd) (2 × 10 4 ) were coated onto 96-well plates and incubated overnight at 37°C. After washing five times with phosphate-buffered saline (PBS), the plates were fixed with 1% paraformaldehyde (PFA) and blocked with 3% bovine serum albumin (BSA). MECA79 and MHA112 were serially diluted from 1ng / ml to 300μg / ml. After washing five times in PBST, horseradish peroxidase (HRP)-conjugated goat anti-mouse and anti-rat secondary antibodies were added at 1:10,000 dilution and incubated for 1 hour at room temperature. Binding was detected by adding TMB (3,3',5,5'-tetramethylbenzidine) substrate, and the reaction was stopped by adding TMB stop solution (N600, Thermo Scientific). The absorbance signal was read at 450nm. The fitting curves of the binding affinities of MECA79 and MHA112 were constructed, and the Kd values were 1.41 nM and 0.97 nM, respectively, as shown in Figure 6. The data indicated that the binding affinity of MHA112 was higher (30%) than that of MECA79 (Figure 6). [Example 7]
[0279] MHA112-drug conjugation reduces tumor growth, fibrosis and metastasis Mice were anesthetized with isoflurane and injected subcutaneously into the mammary gland with 4T1 breast tumor cells (1 × 10 per mouse). 51 cell). Starting 9 days after implantation, free taxol or MHA112-taxol was administered intraperitoneally every other day for 24 days. Tumor growth was monitored twice weekly by digital calipers. The tumor size in the MHA112-taxol group was approximately one-third and one-half of the control (phosphate buffered saline-treated) and free taxol groups, respectively, 5 weeks after implantation (p=0.0001) (Figure 7). These results demonstrated the superiority of MHA112-taxol in treating mouse models of breast tumors. The kinetics of drug delivery in LNs is largely unknown. Draining lymph nodes are the primary site of metastasis. These metastatic locations in lymph nodes are extremely difficult to treat even with high doses of systemic administration of chemotherapy drugs, often resulting in significant toxicity and intolerance on the part of the patient.
[0280] MHA112 holds a unique premise of targeting hidden metastatic niches in LNs. Therefore, the effect of LN delivery of MHA112 on tumor populations in LNs was investigated. The extent of MHA112's ability to restore the overall structure of LNs was also investigated. Tumors are known to create a fibrotic environment. 4T1 tumor-draining lymph nodes (TDLNs) were cut by cryosectioning and stained with anti-HEV (sc-19602, SCBT), anti-LYVE1 (ab14917, Abcam), anti-pan-cytokeratin (C2931, Sigma), anti-collagen I (ab34710, Abcam), anti-collagen IV (ab6586, Abcam) and anti-laminin (ab11575, Abcam). DAPI (VECTASHIELD, Vector Laboratories) was used to counterstain cell nuclei. The stained tissue sections were visualized using an EVOSTM FL Auto 2 imaging system. The images in Figure 8 show that the TDLNs of the control and free taxol groups had expanded HEV and lymphatic (LYVE1) areas. The HEV and lymphatic expansion in the MHA112-taxol TDLNs was less than that in the other groups. In addition, pan-cytokeratin showed that primary tumor metastasis in the TDLNs of the MHA112-taxol group was also significantly reduced compared with the other groups. The structural changes of the TDLNs were also examined. As shown in Figure 9, collagen I, IV and laminin expression levels were lower in the MHA112-taxol. This data indicated that the TDLN fibrosis of the MHA112-taxol was improved. [Example 8]
[0281] MHA112-drug conjugation enhanced survival in an in vivo metastatic cancer model To investigate the effect of MHA112-Taxol on tumor metastasis, 4T1 tumor cell lines were gently injected into the portal vein of mouse liver (1 × 10 per mouse). 4Starting 4 hours after implantation, 160 ng of free taxol or MHA112-taxol was administered intraperitoneally every other day for 20 days. Survival was monitored daily. The survival curves in Figure 10 show that the median survival time (MST) of the control and free taxol groups was 36 and 37 days, respectively. The MST in the MHA112-taxol group was significantly longer (p<0.0001), MST=58. [Example 9]
[0282] MHA112-drug conjugation increased survival in the pan02 pancreatic cancer model Mice were anesthetized with isoflurane and Panc02 pancreatic tumor cells were gently injected into the pancreas of the mice. For the Panc02 tumor model, 2 million cells (2 × 10 6 Starting 4 hours after implantation, 160 ng of free taxol or MHA112-taxol was administered intraperitoneally every other day for 20 days. Survival was monitored daily. The survival curves in FIG. 11 show that the median survival time (MST) of the control and free taxol groups was 30 and 32 days, respectively. The MST in the MHA112-taxol group was significantly longer (p<0.001), MST=45.
[0283] Materials and methods used in Examples 7 to 9 Antibody-drug conjugates Glutaric anhydride (100 mg, Sigma-Aldrich) and taxol (33 mg, LC laboratories) were prepared in a 4 mL vial dried under high vacuum for 24 h and dissolved in 1 mL of pyridine. The solution was stirred at room temperature under Ar atmosphere for 2 h. The reaction was quenched by removal of the solvent under high vacuum for 2 h. 2'-Glutaryltaxol was purified by reversed-phase HPLC (Phenomenex Luna 5 μm C18 250 × 10.0 mm, flow rate 2 mL / min, UV 250 nm detection) using a gradient solvent system (15% to 75% ACN / H2O with 0.1% formic acid in 40 min). 2'-Glutaryltaxol (0.2 mg) dissolved in DMSO (Thermo Scientific Fisher) was activated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC, 0.4 mg, Sigma-Aldrich) and sulfo-NHS (N-hydroxysulfosuccinimide) (1.1 mg, Thermo Scientific Fisher) in MES buffer (pH 6.0, Thermo Scientific Fisher) at room temperature for 15 min (final solution; approximately 1 mL in 10% DMSO). EDC was quenched by 2-mercaptoethanol (1.4 μL, Sigma-Aldrich) for 10 min. The pH of the solution was immediately increased to approximately 8 by Na2CO3 (0.1 M, Sigma-Aldrich). MHA112 dissolved in PBS (pH 7.4, Corning) was mixed with activated 2'-glutaryl taxol for 2 hours at room temperature (1:20 molar ratio of MHA112 to taxol, final solution; 10% DMSO). Dialysis was given through two centrifugal filters (Amicon®, 10 kD MWCO, Sigma-Aldrich) at 10,000 rpm for 15 minutes to remove free taxol. The solution was further purified by a desalting column (Zeba™, 7 kD MWCO, Thermo Scientific Fisher).
[0284] Other embodiments Although the present invention has been described in conjunction with its detailed description, it should be understood that the foregoing description is intended to be illustrative, and not limiting, of the scope of the invention as defined by the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. The present invention includes the following embodiments. [1] (a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and (b) a light chain variable region (VL) comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10 An anti-peripheral lymph node addressin (PNAd) antibody or a PNAd-binding fragment thereof comprising the above. [2] The monoclonal antibody or PNAd-binding fragment thereof described in [1] above, wherein the VH comprises a VH framework region 1 (FR1) having the amino acid sequence shown in SEQ ID NO: 11, a VH FR2 having the amino acid sequence shown in SEQ ID NO: 12, a VH FR3 having the amino acid sequence shown in SEQ ID NO: 13, and a VH FR4 having the amino acid sequence shown in SEQ ID NO: 14. [3] The monoclonal antibody or PNAd-binding fragment thereof according to [1] or [2] above, wherein the VL comprises a VL FR1 having the amino acid sequence shown in SEQ ID NO: 15, a VL FR2 having the amino acid sequence shown in SEQ ID NO: 16, a VL FR3 having the amino acid sequence shown in SEQ ID NO: 17, and a VL FR4 having the amino acid sequence shown in SEQ ID NO: 18. [4] An antibody or a PNAd-binding fragment thereof according to any one of [1] to [3] above, wherein the VH comprises the amino acid sequence shown in SEQ ID NO: 2. [5] An antibody or a PNAd-binding fragment thereof according to any one of [1] to [3] above, wherein the VL comprises the amino acid sequence shown in SEQ ID NO: 7. [6] The antibody or PNAd-binding fragment thereof described in [1] above, wherein the VH comprises the amino acid sequence shown in SEQ ID NO: 2 and the VL comprises the amino acid sequence shown in SEQ ID NO: 7. [7] An antibody or a PNAd-binding fragment thereof according to any one of [1] to [6] above, which is a monoclonal antibody. [8] The antibody or PNAd-binding fragment thereof according to any one of [1] to [7] above, which is a mouse antibody. [9] An antibody or a PNAd-binding fragment thereof according to any one of [1] to [7] above, which is a chimeric antibody.
[10] An antibody or a PNAd-binding fragment thereof according to any one of [1] to [7] above, which is a humanized antibody.
[11] The antibody or PNAd-binding fragment thereof according to any one of [1] to
[10] above, which is an antibody.
[12] The antibody or PNAd-binding fragment thereof according to
[11] above, which comprises human-derived heavy and light chain constant regions.
[13] The antibody or PNAd-binding fragment thereof according to
[11] or
[12] above, which comprises a heavy chain constant region of the isotype immunoglobulin mu (IgM).
[14] The antibody or PNAd-binding fragment thereof according to any one of [1] to
[10] above, which is a PNAd-binding fragment of the antibody.
[15] The antibody or PNAd-binding fragment thereof according to
[14] above, wherein the PNAd-binding fragment is selected from the group consisting of a single-chain Fv fragment (scFv), a F(ab') fragment, a F(ab) fragment and a F(ab')2 fragment.
[16] An antibody or a PNAd-binding fragment thereof according to any one of [1] to
[15] above, which is conjugated to a drug.
[17] The antibody or PNAd-binding fragment thereof according to
[16] above, wherein the agent is a contrast agent, a cytotoxic agent or a drug.
[18] The antibody or PNAd-binding fragment thereof according to
[16] above, wherein the drug is a drug-containing polymer particle.
[19] The antibody or PNAd-binding fragment thereof described in
[18] above, wherein the drug-containing polymer particle contains an immunosuppressant or immunomodulatory drug.
[20] The antibody or PNAd-binding fragment thereof according to any one of
[16] to
[19] above, wherein the conjugation is a covalent conjugation.
[21] The antibody or PNAd-binding fragment thereof according to any one of
[16] to
[19] above, wherein the conjugation is via a linker.
[22] The antibody or PNAd-binding fragment thereof according to
[21] above, wherein the linker is polyethylene glycol.
[23] A polynucleotide comprising a nucleic acid sequence encoding the antibody or PNAd-binding fragment thereof described in any one of [1] to
[15] above.
[24] A polynucleotide comprising a nucleic acid sequence encoding a heavy chain variable region (VH), wherein the VH comprises the amino acid sequence shown in SEQ ID NO:2.
[25] A polynucleotide comprising a nucleic acid sequence encoding a heavy chain, said heavy chain comprising a heavy chain variable region (VH), said VH comprising the amino acid sequence set forth in SEQ ID NO:2.
[26] A polynucleotide according to
[24] or
[25] above, comprising the nucleic acid sequence shown in SEQ ID NO:1.
[27] A polynucleotide comprising a nucleic acid sequence encoding a light chain variable region (VL), wherein the VL comprises the amino acid sequence set forth in SEQ ID NO:7.
[28] A polynucleotide comprising a nucleic acid sequence encoding a light chain, said light chain comprising a light chain variable region (VL), said VL comprising the amino acid sequence set forth in SEQ ID NO:7.
[29] The polynucleotide according to
[27] or
[28] above, comprising the nucleic acid sequence shown in SEQ ID NO:6.
[30] A vector comprising the polynucleotide according to
[24] or
[27] above, operably linked to a promoter.
[31] A vector comprising the polynucleotide described in
[25] above, operably linked to a promoter.
[32] A vector comprising the polynucleotide described in
[28] above, operably linked to a promoter.
[33] A vector comprising the polynucleotide according to
[25] above operably linked to a first promoter and the polynucleotide according to
[28] above operably linked to a second promoter.
[34] A host cell comprising the polynucleotide according to
[24] or
[27] above, wherein the polynucleotide is operably linked to a promoter.
[35] A host cell comprising the polynucleotide according to
[25] or
[28] above, wherein the polynucleotide is operably linked to a promoter.
[36] A host cell comprising the vector described in
[30] above.
[37] A host cell comprising the vector according to
[31] above and the vector according to
[32] above.
[38] A host cell comprising the vector described in
[33] above.
[39] A method for producing an anti-peripheral lymph node addressin (PNAd) antibody or a PNAd-binding fragment thereof, comprising: (a) culturing a host cell described in
[35] ,
[37] or
[38] above; and (b) isolating the antibody from the culture.
[40] A pharmaceutical composition comprising a therapeutically effective amount of the antibody or PNAd-binding fragment thereof described in any one of [1] to
[17] above and a pharma- ceutical acceptable carrier.
[41] A pharmaceutical composition comprising a therapeutically effective amount of the antibody or PNAd-binding fragment thereof according to
[18] or
[19] above and a pharma- ceutical acceptable carrier.
[42] A method for suppressing a lymphocyte-mediated immune response in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in
[40] or
[41] above.
[43] A method for treating or delaying the progression of autoimmune diabetes in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in
[40] or
[41] above.
[44] A method for treating lymphocyte-mediated inflammation in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in
[40] or
[41] above.
[45] A method for treating or reducing metastasis of a peripheral lymph node addressin (PNAd)-expressing malignant tumor in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in
[40] or
[41] above.
[46] The method according to
[45] above, wherein the PNAd-expressing malignant tumor is lymphoma.
[47] A method for delivering a drug to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in
[41] above, wherein the drug delivered to the subject is a drug-containing polymeric particle conjugated to an antibody or a PNAd-binding fragment thereof.
[48] The method of claim 47, wherein the drug is delivered to one or more lymphatic tissues or one or more sites of chronic inflammation in the subject.
Claims
1. (a) a heavy chain variable region (VH) comprising a VH complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 3, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and (b) a light chain variable region (VL) comprising a VL CDR1 comprising the amino acid sequence of SEQ ID NO:8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:
10. An anti-peripheral lymph node addressin (PNAd) antibody or a PNAd-binding fragment thereof comprising:
2. (i) the VH has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2; (ii) the VL has at least 90% sequence identity to the amino acid sequence of SEQ ID NO:7; (iii) the VH comprises the amino acid sequence set forth in SEQ ID NO:2; (iv) the VL comprises the amino acid sequence set forth in SEQ ID NO:7; or (v) the VH comprises the amino acid sequence set forth in SEQ ID NO: 2, and the VL comprises the amino acid sequence set forth in SEQ ID NO: 7; An anti-PNAd antibody or a PNAd-binding fragment thereof according to claim 1.
3. An anti-peripheral lymph node addressin (PNAd) antibody or a PNAd-binding fragment thereof, comprising a heavy chain variable region (VH) consisting of the amino acid sequence of SEQ ID NO: 2 and a light chain variable region (VL) consisting of the amino acid sequence of SEQ ID NO:
7.
4. An anti-PNAd antibody or a PNAd-binding fragment thereof described in any one of claims 1 to 3, wherein the anti-PNAd antibody comprises human-derived heavy and light chain constant regions.
5. An anti-PNAd antibody or a PNAd-binding fragment thereof described in claim 4, wherein the antibody comprises a heavy chain constant region of the isotype immunoglobulin mu (IgM).
6. 6. An anti-PNAd antibody or PNAd-binding fragment thereof according to any one of claims 1 to 5, conjugated to a diagnostic agent.
7. An anti-PNAd antibody or a PNAd-binding fragment thereof described in any one of claims 1 to 5, conjugated to a therapeutic agent.
8. The anti-PNAd antibody or its PNAd-binding fragment described in claim 7, wherein the therapeutic agent is a cytotoxic agent, a drug or a drug-containing polymeric particle.
9. The anti-PNAd antibody or its PNAd-binding fragment described in claim 8, wherein the drug is tacrolimus, mycophenolic acid, mofetil, cyclosporine, sirolimus, fingolimod, myriocin, cyclophosphamide, corticosteroids, rapamycin, mycophenolic acid, mofetil, checkpoint inhibitors, anti-inflammatory agents, chemotherapeutic agents, anti-CD3 antibodies, anti-CD25 antibodies, anti-IL6 antibodies, anti-CTLA-4 antibodies, adalimumab, anti-CD52 antibodies, metabolic antagonists, alkylating agents, anthracyclines, antibiotics or mitotic inhibitors, or is an immunosuppressant, immunomodulatory agent or cytotoxic agent.
10. A polynucleotide comprising a nucleic acid sequence encoding an anti-PNAd antibody or a PNAd-binding fragment thereof according to any one of claims 1 to 5.
11. A vector comprising the polynucleotide of claim 10 operably linked to a promoter.
12. A host cell comprising the polynucleotide of claim 10 or the vector of claim 11.
13. A method for producing an anti-PNAd antibody or a PNAd-binding fragment thereof, comprising: (a) culturing a host cell described in claim 12; and (b) isolating the anti-PNAd antibody or a PNAd-binding fragment thereof from the culture.
14. A pharmaceutical composition comprising a therapeutically effective amount of an anti-PNAd antibody or PNAd-binding fragment thereof according to any one of claims 1 to 5 and a pharma- ceutically acceptable carrier.
15. A pharmaceutical composition comprising a therapeutically effective amount of the anti-PNAd antibody or PNAd-binding fragment thereof of claim 6 and a pharma- ceutically acceptable carrier.
16. A pharmaceutical composition comprising a therapeutically effective amount of an anti-PNAd antibody or PNAd-binding fragment thereof according to any one of claims 7 to 9 and a pharma- ceutically acceptable carrier.
17. 17. A pharmaceutical composition according to any one of claims 14 to 16 for suppressing a lymphocyte-mediated immune response or treating lymphocyte-mediated inflammation in a human subject.
18. A pharmaceutical composition according to any one of claims 14 to 16 for treating or delaying the progression of an autoimmune disorder in a human subject.
19. A pharmaceutical composition described in any one of claims 14 to 16 for treating or reducing metastasis of a PNAd-expressing malignant tumor in a human subject.
20. The pharmaceutical composition of claim 18, wherein the autoimmune disorder is type 1 diabetes or rheumatoid arthritis.
21. The pharmaceutical composition described in claim 19, wherein the PNAd-expressing malignant tumor is lymphoma, breast cancer or pancreatic cancer.
22. A composition comprising an anti-PNAd antibody or a PNAd-binding fragment thereof described in any one of claims 1 to 6, for use in a method for diagnosing an autoimmune disorder or metastasis of a PNAd-expressing malignant tumor in a human subject.
23. The composition described in claim 22, wherein the autoimmune disorder is type 1 diabetes or rheumatoid arthritis.
24. The composition described in claim 22, wherein the PNAd-expressing malignant tumor is lymphoma, breast cancer or pancreatic cancer.
25. A composition comprising an anti-PNAd antibody or PNAd-binding fragment thereof described in any one of claims 1 to 9 for use in a method for delivering a diagnostic or therapeutic agent to a human subject, wherein the diagnostic or therapeutic agent is delivered to one or more lymphatic tissues or one or more sites of chronic inflammation in the human subject.
